b e h r n g e r n g e l h e n n u l r e p r value innovationf n ci l h gh l ig h ts um ar r ep r amount million eur indicate change net sale region america europe asiaaustraliaafrica aaa business human pharma summary report animal health biopharmaceutical contract manufacturing discontinue operation research development expense personnel expense average number employee operate income operating income net sale group profit net sale group equity return group equity investment tangible asset depreciation tangible asset product human pharma product animal health net sale million eur change net sale million eur change jardiance nexgard spiriva frontline trajenta jentadueto heartgard pradaxa ingelvac circoflex flexcombo v e r v e w core leitbild group management report consolidate financial statement product portfolio company make new well medicine human animal heart mission create breakthrough therapy change live independent familyowne boehringer ingelheim freedom pursue longterm vision look ahead identify health challenge future target area need good worldleading researchdriven pharmaceutical company employee create value innovation daily business area human pharma animal health biopharmaceutical contract manufacturing boehringer ingelheim achieve net sale billion euro significant investment billion euro rd drive innovation enable generation medicine save life improve quality life realize scientific opportunity embrace power partnership diversity expert lifescience community work accelerate delivery medical breakthrough transform live patient generation comec n e n core leitbild shareholder perspective key aspect corporate body group management report information group report economic position report opportunitie risk report expect development consolidate financial statement overview select consolidated company consolidate balance sheet consolidated profit loss statement cash flow statement statement change group equity note consolidate financial tatement independent auditor report product portfolio human pharmaceutical respiratory disease cardiovascular metabolic disease oncology disease central nervous system infectious disease animal health livestock swine livestock cattleruminant livestock poultry veterinary public health vph companion animal horse companion animal pet boehringer ingelheim annual report shareholder perspective shareholder perspective look successful financial year boehringer ingelheim important contribution human animal health medicine improve quality life give patient year live possible rely power innovation decade invest sustainably continuously increase extent innovative strength basis company independence reach patient need competitive offer need fulfil promise quality convince value contribution past year special year shareholder company especially colleague involve make health mmh initiative mmh celebrate tenth anniversary year foundation mmh make important contribution improve healthcare people worldwide c urrently social entrepreneur active mmh network country impressive record young initiative timeless mission sincere thank employee great personal commitment contribute development boehringer ingelheim past year lay foundation successful future sign christian boehringer chairman shareholder committeethe board manage director michel pairet carinne brouillonthe board manage director hubertus von baumbach michael schmelmer jean scheftsik de szolnok boehringer ingelheim annual report learn day personal environment medium great need innovative medicine new therapy urgently need common disease rare affect live health boehringer ingelheim set goal make decisive contribution improve human animal health task inspire drive day focus disease great medical need lack therapeutic option outbreak african swine fever covid remind pharmaceutical progress human veterinary medicine continue highly important society advantage advance science offer new approach rely strength develop year company history human pharma business work clinical preclinical research development project involve new active ingre dient year active ingredient test clinical environment time percent active ingredient pipeline come collaboration exter nal researcher bridge gap industry science essential research collaborate project academic institution continent example fund basic biomedical research research institute molecular pathology imp vienna imp enjoy excellent reputation decade drug help save human life example assume launch jardiance extend life type diabetes patient treat million patientyear continue treatment actilyse remain vital irreplaceable medicine million stroke patient worldwide year market launch development innovative active ingredient topic sustainability play increasingly important role drug development year launch reusable respimat inhaler respiratory product spiriva spiolto reusable respimat eliminate metric ton plastic waste metric ton co emission key aspect area animal health consequence african swine fever hit customer china particularly hard unfortunately insidious virus development vaccine challenge take long time face challenge p artners china europe way new product initiate clinical trial worldwide year receive product approval include articell forte europe stem cellbase veterinary therapy treatment lameness horse boehringer ingelheim strong flexible production network network pro duction medicine europe continue play important role order remain com petitive long term current investment program expansion european produc tion facility volume billion euro year inaugurate new production facility biopharmaceutical product vienna single large capital investment company plan use facility production portfolio party contract manufacture important milestone bio pharmaceutical contract manufacturing market approval biologic produce boehringer ingelheim shanghai chinese market successful year term performance enable strengthen basis independence allow investment innovation rd urgently need drug capital investment like thank customer trust partner support spe cial thank employee lay foundation success past year future pioneer respective field share goal contri bution human animal health signed sign sign hubertus vo n baumbach carinne brouillon michel pairet signe signe jean scheftsik de szolnok michael schmelmer corporate body shareholder committee board manage director christian boehringer hubertus von baumbach chairman shareholders committee chairman board manage director christoph boehringer carinne knochebrouillon member board manage director erich von baumbach jr human pharma isabel boehringer dr joachim hasenmai member board manage director dr mathias boehringer animal health prof dr dr andreas barner allan hillgrove member board manage director human pharma advisory board dr andreas neumann member board manage director egbert appel human resource chairman advisory board trustee martin hilti family trust dr michel pairet president hilti foundation member board manage director innovation dr nikolaus von bomhard chairman advisory board jean scheftsik de szolnok chairman supervisory board member board manage director mnchener rckversicherungsgesellschaft ag animal health dr andreas kreimeyer michael schmelmer member board executive director member board manage director research executive director basf se finance finance group function dr frank mastiaux chief executive officer ceo enbw energie badenwrttemberg ag jan rinnert chairman board manage director ceo heraeus hold gmbhpage g r u p n g e e n r e p r information group group business model research development production sustainability occupational safety environmental protection employee report social responsibility report economic position macroeconomic environment earning position development business financial position net asset position report opportunitie risk opportunitie risk management individual risk overall statement risk situation report expect development troper tnemeganam puorg boehringer ingelheim annual report group management report information group group business model foundation year ago boehringer ingelheim develop researchbase pharmaceutical company headquarter ingelheim rhein germany company familyowne found world lead pharmaceutical compa ny aim business activity sustainably improve health quality life human animal germany researchintensive company boehringer ingelheim concen trates research medicine offer therapy disease satisfactory treatment option currently unavailable provide entire value chain research development rd production commercialization product global level day employee create value innovation company business human pharma animal health biopharmaceutical contract manufacturing boehringer ingelheim generate net sale billion eur business share overall sale human pharma business core focus boehringer ingelheim activity numerous company product standard treatment medicine jardiance strong human pharma business develop positively financial year time revenue contributor strong revenue contributor segment jardiance medicine treatment type diabete time reduce risk cardiovascular disease type diabetic preexist cardi ovascular condition follow medicine play significant role boehringer ingelheim success spiriva treatment chronic obstructive pulmonary disease copd unmesta tszearllsee n abchy g besuchsifntene sin group million eur biopharmaceutical contract manufacturing sale million eur million eur animal health human pharma million eur million eur group management report information group net sale region million eur europe asia australia africa aaa americas asthma pradaxa prevent stroke patient atrial fibrillation pre vention treatment thromboembolic disorder trajenta treatment type diabete ofev treatment rare fatal respiratory disease idiopathic pulmonary fibrosis ipf increasingly indication systemic sclerosis intersti tial lung disease sscild likewise provide significant contribution company growth boehringer ingelheim animal health business big provider veterinary vaccine medicine strong presence livestock pet segments merger world market result consolidation animal health market boehringer ingelheim market leader germany secondlarg provider global level net sale increase pet segment sale plunge swine segment outbreak african swine fever especially china significant product term net sale include antiparasitic nexgard heartgard frontline establish swine vaccine ingelvac circoflex treat porcine circovirus type biopharmaceutical contract manufacture important growth area boehringer ingelheim boehringer ingelheim biopharmaceutical activity comprise manufacture brand marketable product actilyse metalyse praxbind world lead provider process development commercial production biopharmaceutical party industrial customer sale mainly comprise discontinue operation financial year boehringer ingelheim achieve majority sale america europe regions region asiaaustraliaafrica aaa country china report currencyadjuste sale growth human pharma business strategic ignificance group future development make sale laicnanif detadilosnoc stnemetat boehringer ingelheim annual report research development line mission statement boehringer ingelheim goal research develop innovative medicine therapie treatment disease satisfactory treat ment available major emphasis development medicine new approach therapy prevent detect treat chronic disease area need treatment high want major contribution human pharma business field animal health global research network country major facility germany biberach hanover ingelheim usa ridgefield connecticut duluth georgia st joseph missouri austria vienna japan kobe france lyon boehringer ingelheim continue explore opportunity expand exist product portfolio organic growth include cooperation external partner build cooperation academic institution biotech company public research institution global research network comprise facility research activity rd expense field development project technology supplement important cooperation increase license agreement key component boehringer ingelheim innovation strategy supple net sale mentation broad rd portfolio partnership especially scientific area collaborate active project academic institute span continent strengthen group innovative prowess human pharma aim new molecule pipeline come external innovation research development expense million eur net sale human pharma expense million eur human pharma net sale animal health expense million eur animal health net sale average number employee investment tangible asset investment infrastructure million eur boehringer ingelheim expand research network purchase share swiss biotech company amal therapeutic sa concentrate cancer immunotherapy research network develop innovative therapeutic cancer vaccine acquisition important step strengthen expand boehringer ingelheim position research immunooncological cancer therapy boehringer ingelheim agree collaborate south korean pharmaceutical company yuhan corpo ration treat nonalcoholic steatohepatitis nash cooperation license agreement focus therapy main cause disease steatosis inflammation scar group management report information group rd site animal health ah human pharma hp americas europe asia oceania brazil germany australia paulnia ah biberach hp sydney ah hanover ah mexico ingelheim rhein ah china g uadalajara tateposco ah katharinenhofrohrdorf ah beijing ah shanghai ah usa france taizhou ah ame ah lyon ah athens colbert ah saintvulbas ah japan uluth ah kobe hp f ulton ah netherlands tokyo ah gainesville ah lelystad ah n orth brunswick ah new zealand ridgefield hp austria auckland ah saint joseph ah innsbruck hp sioux center ah vienna hp switzerland geneva hp bi x boehringer ingelheim digital laboratory grow employee past year agile development team transfer innovative digital product company business exam ple farmera platform help swine farmer livestock healthy enhance productivity smart employ selflearning algorithm increase efficiency biopharmaceutical production line laicnanif detadilosnoc stnemetat boehringer ingelheim annual report boehringer ingelheim venture fund drive innovation strategic invest ment earlystage science technology venture fund invest biotech startup compa ny innovative concept technology potential provide groundbreake therapeutic platform venture fund create company identifie promise research project university academic institution biomedical research institute imp vienna austria largely fund boehringer ingelheim scientist country carry research molecular cellular mechanism form basis complex biological phenomena boehringer ingelheim rd activity basis company sustainable success innova tive capability play key role group positive business development past year inhouse rd supplement external cooperation partnership continue priority future financial year employ average people rd facility total billion eur invest research development new medicine level correspond group net sale human pharma new century commit improve life patient focus substance human pharma rd lie cardiovascular metabolic disease oncology respiratory disease human pharma portfolio immunology disease central nervous system cns retinal health end new substance include human pharma development portfolio clinical preclinical project work development registration selection important research development project show hereinafter development pipeline end phase cardiovascular metabolic disease glpr gcgr agonist phase amylin analog phase hemodynamic modulator phase empalinamet xr combination empaglifozin linagliptin und metformin registration approval appetite modulator phase empagliflozin new indication phase iii sglt inhibitor tdm empagliflozin new indication phase iii sglt inhibitor ckd empagliflozin new indication phase iii sglt inhibitor chf group management report information group development pipeline end phase oncology pd antibody phase mrna vaccine phase vegfang antibody phase lag antibody phase smacmimetic phase bet inhibitor phase lrp inhibitor phase mdmp antagonist phase sirp antagonist phase soskra inhibitor phase mek inhibitor phase recombinant vaccine phase xentuzumab bi phase ii igf antibody mbc respiratory disease autotaxin inhibitor phase nonreceptor tyrosine kinase inhibitor phase cysteine protease inhibitor phase leukocyte protease inhibitor phase phosphodiesterase inhibitor phase bi phase ii enac inhibitor cf nintedanib new indication registration triple angiokinase inhibitor pfild approval nintedanib new indication registration triple angiokinase inhibitor sscild approval immunology nuclear receptor antagonist phase epithelial barrier stress modulator phase receptor serinethreonine kinase inhibitor phase spesolimab bi phase ii ilr antibody gpp spesolimab bi phase ii ilr antibody ppp spesolimab bi phase ii ilr antibody atd spesolimab bi phase ii ilr antibody ulcerative colitis spesolimab bi phase ii ilr antibody cd crohns disease bi phase ii nuclear receptor antagonist psoriasis laicnanif detadilosnoc stnemetat boehringer ingelheim annual report development pipeline end phase central nervous system disease trpc inhibitor phase bi phase ii pde inhibitor fep bi phase ii pde inhibitor rex bi phase ii glyt inhibitor cia bi phase ii glyt inhibitor ad retinal health neuronal damage modulator phase vegf ang antibody phase bi phase ii aoc inhibitor diabetic retinopathy indication abbreviation ad alzheimer disease ckd chronic kidney disease rex r eduction relapse atd atopic dermatitis fep episode psychosis schizophrenia cd crohn disease gpp generalize pustular psoriasis sscild ystemic sclerosis associate interstitial cf cystic fibrosis mbc metastatic breast cancer lung disease chf congestive heart failure pfild p rogressive fibrose tdm type diabetes mellitus cias c ognitive impairment interstitial lung disease schizophrenia ppp palmoplantar pustulosis partner project acquire asset study complete submission ongoing key pipeline advance aprildecember approve systemic sclerosisassociate ild boehringer ingelheim therapeutic area cardiovascular metabolic disease contain company core product diabetes portfolio alliance eli lilly important research datum publish heart failure progressive debilitate potentially fatal condition lead cause hospi talization europe half people heart failure expect die year diagnosis boehringer ingelheim eli lilly alliance announce initiation empulse sixth phase iii study empagliflozin heart failure program consist emperorreduce emperorpreserve emperialpreserve empavision study study investigate effect empagliflozin heart failure relate outcome functional capacity patient heart failure include type diabe tes building legacy innovative treatment range cardiovascular metabolic condi tion rd strategy take holistic view need cardio metabolic disease patient multiple relate condition pursue wave innovative medicine obesity kidney liver disease include nonalcoholic steatohepatitis nash group management report information group focus oncology research cancer develop novel therapeutic approach address unmet need lung gastrointestinal cancer advance broad pipeline cancer celldirecte agent immune oncology therapie combination approach successfully advanced range research program area new development project test people time scientific research new therapeutic concept help patient respiratory disease continue high importance boehringer ingelheim focus area leverage extensive expertise respiratory medicine inflammation fibrosis target broad range inter stitial lung disease include indication ipf systemic sclerosisassociate interstitial lung disease sscild lung disease high unmet need cystic fibrosis severe asthma datum readout phase iii data set nintedanib sscild sencsis trial progressive fibrose interstitial lung disease pfild inbuild trial occur base datum filing regulatory approval respective indication submit approval ofev slow rate decline pulmonary function patient sscild grant japan country new respimat reusable launch country boehringer ingelheim continuously develop immunology rd activity year ramp capacity series dermatological gastroenterological indication year risankizumab originally discover research activity partner abbvie receive marketing approval commercialize abbvie major geography important neuropsychiatric disease schizophrenia depression continue center boehringer ingelheim research central nervous system disease whilst medical need high number patient increase scientific challenge extremely high boehringer ingelheim take challenge remain optimistic develop effective therapy treatment neuropsychiatric disease clinical investigation program encompass aspect early treatment option point symptom physical disor der disturbing pronounce potentially detect eg voice analysis favorably impact avoid dramatic development boehringer ingelheim expand global research development activity tackle boehringer ingelheim eye disease specifically affect eye science innovation core extend research comprehensive pipeline portfolio company build retinal health asset spectrum retinal health clinical development aim prevent visual impairment blindness effective possible addition building strength core therapeutic area capture synergy focus research platform ofev good example area immune modulation fibrosis work combine new approach focus common pathophysiological mecha nism enable discover new approach accelerate development new medicine laicnanif detadilosnoc stnemetat boehringer ingelheim annual report follow table show relevant change current clinical study phase iii clinical trial phase change senscis nct double blind phase iii study complete meet primary endpoint randomize placebocontrolle trial evaluating publish new england journal medicine efficacy safety oral nintedanib treatment phase iii senscis trial nintedanib week patient systemic slow loss pulmonary function sclerosisassociate interstitial lung disease patient sscild compare placebo sscild patient take nintedanib show reduction rate decline lung function measure fvc assess week inbuild nct double blind phase iii study complete meet primary endpoint randomize placebocontrolle trial evaluating publish new england journal medicine efficacy safety nintedanib phase iii inbuild trial nintedanib week patient progressive fibrosing slow lung function decline significantly interstitial lung disease pfild overall study population assess annual rate decline force vital capacity fvc week patient fibrose interstitial lung dis ease ild sign progression openlabel longterm extension study phase iii patient include assess safety efficacy bi spesolimab treatment patient general ize pustular psoriasis gpp take previous study bi empakidney nct multinational phase iii patient include randomize doubleblind placebocontrolle clinical trial design evaluate effect empagliflozin kidney disease progression cardiovascular mortality risk people preexist chronic kidney disease type diabetes carolina nct multinational phase iii study complete meet primary endpoint randomize doubleblind placebocontrolle publish journal american medical clinical trial design assess effect lina association gliptin compare glimepiride cardiovascular cv safety adult relatively early type diabete increase cv risk establish cv disease group management report information group animal health rd activity field animal health boehringer ingelheim concentrate innovative vaccine antiparasitic protection livestock pet pharmaceutical product treatment chronic disease goal strengthen animal health mean innovative preventive solution medicine globally orient research development facility focus research new sub stance development future therapeutic solution vaccine base local pathogen pathogen variant imperative present key market region local rd production facility past year create comprehensive database pet livestock disease serve basis focus research development activity disease clinical symptom enter database evaluate base key criterion pathogen affect organ system addition bring articell forte stem cellbase animal health product launch european market treat lameness horse continue work highly articell forte promise innovative digitally integrate diagnostic solution initiate clinical study worldwide receive product authorization addition internal research development analyze external project product integrate portfolio appropriate obtaining approval expand geographical distribution exist product important aspect rd activity laicnanif detadilosnoc stnemetat boehringer ingelheim annual report production facility animal health ah human pharma hp biopharmaceutical contract manufacturing bio americas europe italy asia oceania brazil denmark fornovo hp china itapecerica hp kalundborg ah noventa ah nanchang ah paulnia ah shanghai hp bio germany netherlands taizhou ah mexico biberach bio lelystad ah guadalajara ah dortmund hp indonesia xochimilco hp ingelheim rhein hp austria bogor hp vienna bio puerto rico france japan barceloneta ah lyon ah spain yamagata hp toulouse ah sant cugat hp usa new zealand athens ah greece united kingdom auckland ah fremont bio koropi hp pirbright ah gainesville ah st joseph ah worthington ah production human pharma human pharma business production responsible reliable supply innovative topquality medicine competitive price patient customer ongoing development company internal production facility strategic cooperation external manufacturer establish modern flexible market supply network encompass entire value chain supplier start material worldwide logistic distribution finish pharmaceu tical product boehringer ingelheim production facility concentrate product strategi cally important company stateoftheart case unique manufacturing technology partnership external manufacturer expand production capacity particularly product far advanced term life cycle group management report information group financial year global network include boehringer ingelheim plant coun try group biopharmaceutical facility facility manufacture pharmaceutical active substance produce medical device manufacture finish pharmaceutical product group network optimize facility malgrat spain sell assign important step technology production process facility boehringer ingelheim able ensure patient care delivery capacity patient care high priority boehringer ingelheim company consist ently make important investment development transformation production capaci tie internal external network ingelheim headquarters boehringer ingelheim significant progress implementation key investment industrialization newly develop innovative medicine initial supply market construction plant group sant cugat facility spain complete schedule company mar ket additionally supply respimat technologybase inhalation medicine extension biopharmaceutical site vienna austria create additional inhouse capacity cover increase demand actilyse praxbind ongoing implementation group supply chain strategy optimize value chain management significantly supplier customer endtoend use modern digital automate process technology facilitate transparent efficient management integrate flexible supply chain base global production network animal health animal health product manufacture worldwide sale network animal health production facility country addition boehringer ingelheim internal facili tie company contract manufacturer manufacture product boehringer animal health ingelheim company product portfolio essentially unchanged balanced production facility vaccine pharmaceutical product nutraceutical traditional product supplement country diagnostic product monitor solution include digital application livestock monitoring link livestock owner veterinarian optimization company production network continue remain priority goal ensure robust efficient supply product company sell facility saintherblon france reduce number contract manufacturer investment capacity expansion strong revenue contributor nexgard barceloneta puerto rico facility expansion small animal vaccine produc tion companys facility athens georgia usa cattle vaccine production st joseph missouri usa capacity expansion footandmouth disease vaccine lyon france additional investment development innovative technology manufacture product biopharmaceutical contract manufacturing boehringer ingelheim pursue biopharmaceutical activity facility biberach germany lead vienna austria fremont california usa shanghai china comprise manufacture provider ownbrand marketable product actilyse metalyse praxbind manufacture industrial customer biopharmaceutical clinical testing world lead company process devel opment launch preparation commercial production biopharmaceutical thirdparty indus trial customer pharmaceutical company innovative biotech firm client laicnanif detadilosnoc stnemetat boehringer ingelheim annual report boehringer ingelheim biopharmaceutical contract manufacturing business boehringer ingelheim cover entire biopharmaceutical value chain genetic development production cell follow manufacture active substance filling finish pharmaceutical product product launch global market supply see overall increase use capacity network industrialscale production facility product biberach facility fulfil increase market demand actilyse company facility fremont california usa approval process custom er market product successfully complete possible meet rise product demand network biberach fremont largescale cell culture plant biberach largescale microbial plant vienna customer product successfully approve international authority product plasmid dna gene therapy vienna facility boehringer ingelheim actively examine new therapy option expansion project new industrialscale biopharmaceutical production facility boehringer ingelheim facility vienna reach milestone key function go operation strategic relevance biotechnological production capacity rise context increase importance nbe new biological entity pipeline production delivery hospital product finish pharmaceutical product began schedule shanghai china local market country outside china addition application approval customer product chinese authority successfully complete biopharmaceutical product approve line new regulatory requirement contract manufacturing china approval final milestone pilot project boehringer ingelheim chinese regulatory authority principle cooperation marketing authorization holder contract manufacturer evaluate successfully apply facility shanghai recognize contract manufacturer cmo chinese authority sustainability occupational safety environmental protection protection employee environment sustainable use natural resource promotion environmental awareness major component company mission statement prime importance boehringer ingelheim compliance social environ mental aspect firmly anchor corporate philosophy year ensure achieve sustainability future generation groupwide company develop bind standard term environmental protection health safety work internal guideline reflect respective countryspecific require ment case far standard prescribe law particular follow international standard guidance document work close cooperation relevant association boehringer ingelheim corporate department environment health safety sustainability ehss responsible strategic focus group management report information group start green future choice program develop set new strategic global goal take business growth account program optimize green activity facility business area worldwide factor ing value chain program consider different environmental aspect build facil itie close nature provide habitat variety plant animal encourage green behavior employee adopt measure avoid water air pollution renewable energy reduce waste create environmentally friendly product implement certi fie system environmental protection energy management continuously work co reduce measure facility aim lower absolute co emission focus sustainability major project spend additional million eur year invest green future foster environment friendly energysave investment mean digitalized solution work implement globally efficient process stand ardize software solution global digitalization project collection environmental datum groupwide green program electronic signature solution eh audit system successfully support test implement digitalization approach enable rationalize activity world reduce expenditure suffer quality performance loss boehringer ingelheim aware need active water management program access suffi ciently clean water impact social cultural justice ecological sustainability commer cial benefit introduce water management program facility prone water risk reduce volume medicine leave production wastewater require supplier year october promeco production facility xochimilco mexico award alliance water stewardship aws certification boehringer ingelheim pharma ceutical company worldwide certify globally recognize standard antimicrobial resistance amr pose increasingly threat global public health require action level government business society large reason boehringer ingelheim join amr industry alliance large private coalition establish offer sustainable solution combat antimicrobial resistance boehringer ingelheim support objective nagoya protocol concern aspect biodiversity relevant activity pharmaceutical sector commit ted uphold obligation result acceptance nagoya protocol pursue research development responsible manner safe zero choice program aim reduce number year safe zero workplace accident celebrate tenth anniversary germany addition high choice safety initiative intend promote occupational safety introduce laicnanif detadilosnoc stnemetat boehringer ingelheim annual report employee report grow number boehringer ingelheim employ people average worldwide represent employee increase previous year number staff increase region average number employee region americas europe asia australia africa aaa methodology calculate average number employee revise consolidated financial statement calculate average originally base previous endofquarter figure change assessment base monthend figuresthe figure adjust line new methodology major success factor positive growth group engage motivated staff accord ingly particularly commit actively develop support employee order well prepare challenge ahead comprehensive training system empha size acquisition technical expertise promote social skill integration experience cultural background personality boehringer ingelheim create openness different approach opinion live corporate vision value innovation global company important diversity custom er reflect workforce create work environment embrace diversity differ ence pillar boehringer ingelheim corporate culture contribute factor company success addition competitive salary boehringer ingelheim offer benefit employee benefit include range company pension plan flexible homebase work option numerous healthrelate benefit significant segment corporate strategy human resource department scope ensure employability staff promote wide range opportunity innovation work support employee nurture talent develop individual vocational training major importance boehringer ingelheim stand social responsibility company offer career opportunity great number young people time tie talented wellqualifie workforce young professional company backdrop demographic change young professional start career boehringer ingelheim germany different scientific technical com mercial field training dualstudy course average young people enrol vocational training program group management report information group company aim strengthen appeal boehringer ingelheim employer current future employee boehringer ingelheim receive employer award area auditor international independent employer institute addition germany boehringer ingelheim receive award argentina brazil china italy indonesia colombia malaysia austria philippines poland romania russia singapore spain south korea thailand vietnam social responsibility boehringer ingelheim power people actively promote diverse coop erative open work environment employee difference value respected diversity make right mix inclusion bring good result mix concentrate encourage respectful environment comprehensive diversity inclusion action plan place promote diversity parameter necessary core issue include activity diversity network new recommendation respect ful communication boehringer ingelheim official member diversity charter early proutemployer acknowledge prout work foundation take social responsibility important aspect corporate culture commitment wellbee patient employee family focus wide range project important involved social interaction region active company main focus social engagement support people need help center human person boehringer ingelheim activ itie focus protect maintain environment major pillar social commitment make health mmh initiative start continuously develop social entrepreneurship movement company externally socially entrepreneurial sustainable activity limit indi vidual project relate region issue instead initiative focus creatively connect local international partner different sector network tra ditional visible invisible border central element successful social movement order identify promote implement innovative solution farreache complex challenge healthcare sector cocreation bridge social commercial entrepreneurship bring social entrepreneur nonprofit organization health care sector boehringer ingelheim employee resource date mmh network boehringer ingelheim ashoka world large nonprofit organization help social entrepreneur reach approximately million people worldwide area health care laicnanif detadilosnoc stnemetat boehringer ingelheim annual report mmh initiative aim promote employee commitment social entrepreneurship order advance health care project different country work local external partner colleague boehringer ingelheim mmh leadership program rural southern india insight india kenya insight kenya participation social intrapreneurship online course opportunity collaborate social entrepreneur mmh network executive residence internal competition promote employee project hone staff social entrepreneurial thinking activity strengthen network philosophy partnership nonprofit organization social enterprise health care sector large number local project take shape employee actively involve improve health mean understand people environment everyday challenge offer solution need health awareness affordability accessibility health service acceptance play key role mmh play role university sector goal help student lecturer learn socially entrepreneurial think practical activity develop ment health carerelate project optimize stroke care europe emerge market boehringer ingelheim establish angel initiative european stroke organisation eso world stroke organization wso stroke alliance europe safe national stroke association compa ny initiative achieve goal develop network clinic europe ensure stroke patient treat line define standard worldwide clinic country support boehringer ingelheim support german center infection research dzif project develop covid medication therapy new coronavirus sarscov development monoclonal antiviral body development aim complete molecule discovery effort month boehringer ingelheim continue pursue lastmile program support global alliance livestock veterinary medicine galvme funding bill melinda gates foundation integrate solutionoriented initiative aim respond critical challenge field animal health ensure consistent availability medical resource animal hard toaccess area subsaharan africa project boehringer ingelheim help small farmer gain access veterinary medicine local level newly approve medicine new employ ment opportunity technical regulatory field positive effect wellbee animal people lastmile country underline boehringer ingelheim strong social commitment aim positive impact human animal live area particularly vital need employee getting involve large variety local initiative company order help people need case environmental catastrophe everyday situation provide technical support time provide medical nursing care group management report report economic position report economic position macroeconomic environment world economy suffer noticeable loss momentum past year world economic growth rate record low level financial economic crisis trade policy tension china united kingdoms brexit negotiation eu grow global uncertainty domestic international political measure prompt uncertainty investor result strong decrease investment activity growth slowdown affect advanced economy emerge economy equal measure significance individual country vary depend nature trading activity overall condition direct strong impact cyclical industry pharmaceu tical market characterize performance capability national economy par ticular demographic development society global pharmaceutical market register growth rate financial year source iqvia trend drive rise demand industrialize country innovative medi global pharmaceutical cine age population industrialize nation well access medical care market continue industry growth remain positive surpassed figure previous year grow growth healthcare cost percentage gross domestic product country mean government payor pressure control regulate healthcare expenditure strongly past sustain public political pressure contain price pharmaceutical costcutte measure impose government payor include governmentimpose industrywide price reduction mandatory reference price sys tem payor limit access treatment base strict costbenefit analysis import medicine lowercost country expensive one shift burden payment patient high copayment program mandatory substitution generic patent equivalent furthermore protection intellectual property patent etc increase pressure animal health industry focusse livestock pet growth path particular emerge market population growth improve living standard people animal health market characterize rise demand animal protein increase popularity pet hand challenge strategic growth require constant research development innovation bring market addition consolidation merger supplier customer currently lead increase competition boehringer ingelheim respond environment boldness innovative spirit remain determined improve human animal health difficult time laicnanif detadilosnoc stnemetat boehringer ingelheim annual report international monetary fund oecd expect world economy register growth rate similar continued loose monetary policy lead central bank preliminary partial agreement trade conflict china point stabilization united kingdoms expect orderly withdrawal eu positive impact risk realize lead weak growth include particu lar recently emerge viral disease covid coronavirus drastic consequence people world economy repeat escalation trade dispute worsen geo political tension spillover industrial sector weakness overall economy weather relate natural disaster global activity boehringer ingelheim depend currency development particular usd japanese yen addition chinese renminbi increase importance currency major significance boehringer ingelheim positive impact sale past year significant currency risk hedge suitable financial instrument currency development effect net sale average rate basis eur million eur dollar japanese yen chinese renminbi earning position guide principle value innovation longterm corporate strategy intend secure company independence improve human animal health base new futureoriented therapy area high medical need core boehringer ingelheim strategic focus require stable earning position solid financing base near term boehringer ingelheim record net sale million eur financial year corre spond increase compare previous year level million eur billion eur sale exchange rate development foreign exchange market associate exchange rate effect positive impact sale trend adjust effect group grow sale million eur share overall sale america region remain boehringer ingelheim key sale market america region sale increase yearover year currencyadjuste sale europe region rise million eur currencyadjuste group achieve sale region growth drive market germany spain great britain russia poland french market unable match previous year sale volume asiaaustraliaafrica aaa region realize strong growth currencyadjuste revenue million eur generate region correspond share group total revenue strategically important chinese market provide company overall sale volume represents currencyadjuste increase yearoveryear growth animal health business china negatively affect outbreak african swine fever group management report report economic position net sale region million eur currency change adjust america growth europe region asiaaustraliaafrica aaa support good result clinical trial cooperation external partner place new product market successfully push ahead wellestablishe product human pharma business hand result animal health business nega tively affect outbreak african swine fever asia particular increase consoli dation animal health industry key figure million eur change net sale operating income return net sale income taxis income taxis material ratio take consideration change inventory rise slightly mainly attributable increase destruction cost african swine fever personnel expense rise disproportionately slow rate revenue relate high extraordinary effect previous year company workforce increase particularly strategic facility amortization depreciation increase comparison past financial year item include adjustment intangible fix asset human pharma animal health business impairment loss tangible fix asset operating expense rise disproportion ately increase investment research development service purchase project high currency loss hedge yearoveryear operating income include extraordinary effect result impairment loss intangible fix asset restructure measure integration cost reversal provision amount total million eur million eur previous year operating income surpass thank primarily positive operating trend human pharma busi ness boehringer ingelheim record operating income million eur correspond return sale income taxis increase high operating income financial income financial income remains strongly adversely affect decline discount rate pension similar obligation amount million eur financial income improve overall gain plan asset cover pension similar obligation laicnanif detadilosnoc stnemetat boehringer ingelheim annual report income taxis significantly higher previous year reflect favorable course business point previous year particularly burden strong aperiodic tax expense note regard provision german commercial law shareholder personal taxis arise group business activity recognize tax expense instead taxis present withdrawal group equity take specificity account actual tax ratio markedly high figure show profit loss statement despite challenge market condition business area boehringer ingelheim group regis tere positive performance financial year follow group profit million eur million eur previous year figure increase considerably amount million eur group profit development business past financial year boehringer ingelheim activity divide human pharma animal health biopharmaceutical contract manufacturing business net sale business million eur currency change adjust human pharma animal health biopharmaceutical contract manufacturing sale discontinue operation human pharma total group revenue human pharma main pillar boehringer ingel heim business activity human pharma sale amount million eur equivalent growth currencyadjuste compare previous year pos human pharma grow itive sale trend result solid market position establish medicine drive region product jardiancefamily ofev company achieve growth yearover year region despite price pressure particularly establish medicine boehringer ingelheim successfully hold continued pursue reorganization human pharma product portfolio plan type diabete medicine jardiance company big revenue contributor time achieve sale million eur jardiance reporting period correspond increase compare previous year million eur boehringer ingelheim secondstrong product term sale past year spiriva treat chronic obstructive pulmonary disease copd generate sale volume million eur low previous year level million eur expect view product life cycle group management report report economic position trajenta jentadueto treatment type diabete register sale volume million eur growth rate financial year anticoagulant pradaxa achieve increase previous year figure million eur sale volume million eur medicine remain boehringer ingelheim big revenue contributor ofev registered growth rate contribute million eur company successful sale result product treatment idiopathic pulmonary fibrosis increase extend sscild micardi treatment high blood pressure record growth despite increas ing generic competition product family achieve sale million eur million eur actilyse able increase sale million eur million eur launch patient benefit medication despite lose patent protection decade ago biopharmaceutical remain available option immediate treatment case ischaemic stroke worldwide risankizumab medication treatment plaquepsoriasis mainly develop boehringer ingelheim market globally partner abbvie brand skyrizi net sale million eur change jardiance spiriva trajenta jentadueto growth jardiance pradaxa regard regional distribution revenue human pharma business usa large market share boehringer ingelheim generate sale mil lion eur correspond increase compare previous year currency adjust eucan region europe canada australia new zealand secondbigg market account revenue million eur sale increase compare million eur exchange rate effect significant influence sale trend laicnanif detadilosnoc stnemetat boehringer ingelheim annual report strong sale increase past year company emerge market register strong sale growth currency company adjust people republic china key driving force region emerge market currencyadjuste growth rate sale rise million eur previous year million eur japan sale increase million eur currencyadjuste sale previous year amount million eur net sale region million eur change usa europecanadaaustralianew zealand eucan emerge market japan animal health volume sale animal health business amount million eur represents change previous year currencyadjuste net sale million eur change nexgard frontline heartgard ingelvac circoflex flexcombo sale figure negatively affect outbreak african swine fever asia tcm china taiwan hongkong region sale plunge swine vaccine ingelvac circoflex accordingly register strong decline sale million eur increase price pressure perceptible company pet segment swine segment frontline antiparasitic achieve sale million eur low previous year antiparasitic company nexgard product perform strongly environment revenue drive growth million eur million eur growth yearoveryear heartgard antiparasitic achieve growth register sale million eur million eur group management report report economic position horse segment successful realize currencyadjuste growth yearoveryear net sale region million eur change usa eucan alamea tcm asia latin america middle east africa china taiwan hongkong biopharmaceutical contract manufacture biopharmaceutical contract manufacturing business maintain positive performance trend continue strong growth order situation entire business develop positively result high level capacity biopharmaceutical utilization biopharmaceutical production contract manufacturing sale discontinue operation sale mainly contain discontinue operation wind expect dis continue operation aggregate activity minor strategic importance boehringer ingelheim include obligation income result business swap sanofi particular service agreement buscopan business brazil exclude sale financial position million eur financial fund cash flow operating activity cash flow investing activity cash flow financing activity change financial fund cash relevant transaction change financial fund change consolidated company exchange rate movement financial fund boehringer ingelheim financial management instrument method aim securing liquidity ensure appropriate management financial risk financial activity gear support business strategy laicnanif detadilosnoc stnemetat boehringer ingelheim annual report cash inflow operating activity amount million eur represents increase million eur comparison previous year million eur attributable positive business trend cash flow investing activity amount million eur similar level prior year million eur reflect significant investment external innovation strategic infrastructure support business activity high capital particular note rd investment amal therapeutic sa cooperation expenditure volume yuhan corporation soundtalk nv strengthen rd pipeline addition major invest ment fix asset reach milestone investment expan sion production facility vienna biopharmaceutical contract manufacture million eur invest facility significant site group decade boehringer ingelheim major investment new development center bio pharmaceutical medicine bdc biberach bdc foundation stone lay intend create new job increase contract manufacturing capacity focus therapeutic area need treatment high cancer immunological disease million eur invest bdc supplement number significant investment boehringer ingelheim global biopharmaceutical development network important investment animal health business nearly million eur invest new antigen production center regulatory animal disease control jonage france foundation stone major hightech facility lay fall plan overall investment production center million eur intend enable animal health business respond grow demand medicine treat footandmouth bluetongue disease cash outflow financing activity million eur comprise payment million eur charitable boehringer ingelheim foundation support basic research field natural life science payment parent company shareholder mainly pay personal taxis arise group business activity interest pay addition german private placement repay overall take consideration exchange effect change group consolidate company lead increase boehringer ingelheim group financial fund million eur million eur group management report report economic position net asset position million eur change change asset intangible tangible asset financial asset fix asset inventory trade account receivable receivables current asset cash cash equivalent current asset asset total asset equity liability group equity provision pension similar obligation tax provision provision account payable loan thereof residual term year liability liabilitie difference capital consolidation total equity liability financial year boehringer ingelheim total asset amount million eur increase million eur compare previous year million eur growth attributable particular increase volume financial fund cash longterm securi tie grow significantly positive cash flow financial year longterm financial asset increase regard investment cash security despite schedule unscheduled depreciation amortization tangible intangible fix asset increase high volume capital expenditure strategic expansion company business include human pharma research biopharmaceutical vienna austria fremont california usa animal health france work capital receivables inventory especially pick result positive sale trend increase inventory france greece asset likewise increase thank positive market trend plan asset pension similar obligation reason increase higher defer tax asset result temporary difference value consolidate company tax balance sheet value consolidate balance sheet currency effect result increase item asset balance sheet laicnanif detadilosnoc stnemetat boehringer ingelheim annual report equity ratio increase group equity increase million eur group profit positive cur despite high rency difference equity amount million eur december equity ratio balance sheet total improve december spite high balance sheet total addition equity pension provision longterm liability available group long term total item amount million eur december represent share total asset consequently previous year longterm disposable capital cover intangible tangible fix asset work capital pension provision increase germany particularly low actuarial discount rate increase provision correlate change net sale key element represent provision discount usa decrease liability relate liability liability bank trade account payable mainly germany german private placement issue completely repay liability decline mainly release difference arise capital consolidation lower defer tax liability temporary difference boehringer ingelheim positive performance financial year reflect net asset position boehringer ingelheim remain profitable soundly finance company make considerable capital expenditure high rd expenditure ensure longterm growth independence group management report report opportunitie risk report opportunity risk opportunitie risk management assess risk context holistic opportunity risk management endeavor account result opportunity opportunity management base strategy objective company individual business operate business unit integral groupwide planning management system responsible busi ness function bear direct responsibility early systematic identification analysis use opportunity boehringer ingelheim researchdriven innovative pharmaceutical company current research development activity naturally consider relevant opportu nity relevant project outline research development rd chapter look digitalization opportunity new technological possibility area research particularly clinical development support patient therapy aim risk management system implement boehringer ingelheim identify businessspecific risk early possible particularly risk jeopardize continued existence company assess reduce reasonable level mean suitable meas ure person responsible key business function include process calculate assess risk groupwide risk information system ensure identify risk analyze assess carefully follow appropriate classification adequate risk manage ment measure initiate implementation consistently monitor year review internal auditing perform target routine audit extraordinary audits world addition adherence legal requirement internal group guideline main focal point functionality system effectiveness internal control prevention loss asset efficiency structure process correspond adjustment optimization initiate necessary individual risk important risk boehringer ingelheim expose broken follow e specific category financial risk legal risk production environmental risk personnel risk industryspecific risk risk identify concrete appear controllable mean specific management procedure term abstract case risk completely control mean target management procedure regardless probability occurrence financial risk relevant financial risk break follow currency risk credit country specific risk financial investment shareholding risk currency risk global orientation business activity subject opportunity risk exchange rate volatility particularly regard dollar japanese yen group monitor quantifie risk regular interval make predictable future business mean relevant hedging strategy appropriate financial instrument forward exchange contract resultant risk subsequently designate concrete controllable limited laicnanif detadilosnoc stnemetat boehringer ingelheim annual report credit countryspecific risk boehringer ingelheim expose credit countryspecific risk result interna tional business activity portfolio trade account receivable trade account payable identify extraordinary risk group usual level industry apply possible default risk receivables largely hedge economic political risk continue carefully track credit countryspecific risk posi tion respond negative change timely manner risk consider moderate regard concrete financial investment shareholding risk group pursue defensive investment strategy management financial asset reflect orientation portfolio focus european economic monetary union emu government bond credit rating shortterm money market deposit result concrete controllable limited risk limit opportunity major financial investment net book value strategic investment relate company affect market business circumstance lead high level volatility fair market value specific risk cover respective impairment consolidate financial statement legal risk business activity group expose legal risk distinction regulatory liability patent protection risk regulatory risk boehringer ingelheim expose risk arise legal dispute proceeding official investigation legal administrative decision ongoing future proceeding predict regard resultant risk abstract high liability risk marketing sale pharmaceutical expose potential product liability risk boehringer ingelheim currently product liability insurance company risk profile absolutely guarantee insurance coverage maintain reasonable cost acceptable condition sufficient protect boehringer ingelheim claim loss potential claim loss case foreseeable product liability insurance cover partially cover specific liability risk remain risk exposure cover provision moderate risk group furthermore product liability claim tie substantial financial resource management capacity detrimental company image event market consider product unsafe ineffective result unexpected effect moderate abstract risk patent protection risk protection innovation trademark patent right particular importance boehringer ingelheim research company commercial protective right increasingly target attack breach take necessary precaution allow detect threat early stage commence appropriate countermeasure defend legal position legal mean available moderate risk regard concrete group management report report opportunitie risk production environmental risk quality management system compliance process continuously optimize close coop eration relevant authority order ensure compliance cgmp standard current good manufacturing practice risk area continue high significance group classify abstract order guarantee supply product market implement measure guarantee reliable highquality supply internal external customer addition supplier management procurement involve build internal standby capacity result risk concrete risk area environment health safety sustainability ehss preemptively mini mize ensure global adherence high safety standard appropriate emergency plan draw possible incident kind practice subject comprehen sive quality test regular interval result measure risk class concrete limited personnel risk boehringer ingelheim company expose demographic change resultant risk affect lack appropriately qualified personnel potential risk substantial impact company business activity include longterm planning process year gain strategic significance result boehringer ingelheim counter risk mean comprehensive personnel concept con text global personnel management present group opportunity regardless ethnic background gender religion offer company employee development opportunity base professional ability social skill personal aptitude willingness responsibility accordance need company view countermeasure describe risk regard moderate concrete industryspecific risk boehringer ingelheim subject industryspecific business risk pharmaceutical industry risk partly materialize past financial year increasingly important boehringer ingelheim effect consider high abstract addition loss exclusivity product establish market risk associate develop ment registration new product risk increasingly include change restrictive requirement relate pricing reimbursement sale market frequently price pharmaceutical product subject state monitoring regulation price pre sure cheap generic drug cause state reimbursement system boehringer ingelheim keep close eye change sale market take appropriate meas ure response current development overall statement risk situation current perspective aware risk conjunction risk lead lasting impairment company asset financial earning position jeopardize continued existence boehringer ingelheim laicnanif detadilosnoc stnemetat boehringer ingelheim annual report report expect development boehringer ingelheim look successful financial year innova tion available patient previous year contribute significantly health livestock pet achieve ambitious target absolute number compar ison competitor create foundation sustainable corporate development longterm growth look ahead optimistically work passionately continue improve human animal health increasingly difficult market environment pharmaceutical industry combine volatility economic environment make planning capability increasingly challenging outbreak new coronavirus pose multidimensional challenge chinese employee global production network global supply chain rapidly evolve environment advantage opportunity present respond courageously risk materialize ensure continued success market view competitiveness remain important preserve use financial flexibility growth innovation view change unfold health care system face aging population increase price pressure major market especially exclusively core market usa japan europe china expect limited growth impetus pharmaceutical industry come year plan focus strongly animal health customer solution challenge innovation product portfolio spread african swine fever country remain risk priority biopharmaceutical busi ness supply market product contract manufacturing customer completion lscc largescale production facility vienna austria expect boehringer ingelheim achieve slight yearonyear increase net sale comparable basis adjust currency extraordinary effect consistently high rd expenditure increase compatible strategic focus continue drive growth flow new product achieve goal manage rd external innovation general partnership continue pursue strategy invest external rd care close investigation therapeutic benefit associate prospect success flow innova tive medicine research pipeline show short medium longterm growth potential group management report report expect development addition patent expiry attack patent major challenge face researchdriven pharmaceutical industry increase investment rd big hurdle increase cost associate product approval context increase cost pressure health care system outline particularly emphasize system increasingly unwilling substantial investment development new medicine contribute adequately increase efficiency system animal health research like wise require major investment preventive research diagnostic option conjunction long plan development cycle new product make business predictable require quickly recognize seize opportunity human pharma animal health hand subject cost strategy continual monitoring adjustment end launch initiative past year accelerate reaction change reduce organizational complexity low cost base order create potential capital expenditure secure company longterm success backdrop successful taking account expect economic market environment expect operating income comparable basis adjust currency extraordinary effect level fiscal year familyowne company boehringer ingelheim primary aim remain creation value innovation support longterm sustainable organic growth vision preserve company independence competitiveness confident achieve ambitious target thank great innovative strength base comprehensive portfolio prospective product global presence support highly qualified motivated employee business remain committed ambition research develop inno vative product bring market area medical need high break new ground therapeutic approach human animal medicine aim endeavor new medicine available human animal treat effectively new therapy laicnanif detadilosnoc stnemetatspage c n l e f n n c l e e n overview select consolidated company consolidate balance sheet consolidated profit loss statement cash flow statement statement change group equity note consolidate financial statement independent auditor report laicnanif detadilosnoc stnemetat boehringer ingelheim annual report overview select consolidated company ch boehringer sohn ag co kg ingelheim rhein boehringer ingelheim vetmedica gmbh ingelheim rhein argentina italy p taiwan germany p r boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim corporate argentina sa buenos aire italia spa milan taiwan co ltd taipei center gmbh ingelheim rhein australia r japan r thailand boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim pharma australia pty ltd north ryde japan co ltd tokyo thailand limited bangkok gmbh co kg ingelheim rhein boehringer ingelheim microparts belgium mexico usa p r gmbh dortmund boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim venture fund belgium sa brussels mxico sa de cv mexico city usa inc wilmington delaware gmbh ingelheim rhein newport laboratories inc boehringer ingelheim brazil p r netherlands p r wilmington delaware biopharmaceutical gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health brasil ltda paulo netherlands bv velserbroek boehringer ingelheim veterinary research center gmbh co kg hanover canada new zealand p r boehringer ingelheim middle east boehringer ingelheim animal health boehringer ingelheim animal health africa gmbh ingelheim rhein canada inc burlington new zealand limited auckland china p r philippines nanchang boehringer ingelheim boehringer ingelheim animal health animal health co ltd nanchang philippines inc makati city boehringer ingelheim animal health shanghai co ltd shanghai puerto rico p boehringer ingelheim animal health boehringer ingelheim animal health operation china co ltd taizhou puerto rico llc barceloneta boehringer ingelheim vetmedica china co ltd taizhou south africa denmark p boehringer ingelheim animal health south africa pty ltd randburg boehringer ingelheim animal health denmark copenhagen south korea france p r boehringer ingelheim animal health korea ltd seoul boehringer ingelheim animal health france lyon spain great britain p boehringer ingelheim animal health espaa sa barcelona boehringer ingelheim animal health uk limit bracknell distribution p production r research development consolidate financial statement overview select consolidated company ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim international gmbh ingelheim rhein argentina czech republic japan p r serbia boehringer ingelheim sa boehringer ingelheim spol sro nippon boehringer ingelheim co ltd boehringer ingelheim serbia doo buenos aire prague tokyo beograd belgrad boehringer ingelheim seiyaku australia denmark yamagata south africa boehringer ingelheim japan inc boehringer ingelheim pty ltd boehringer ingelheim danmark ingelheim pharmaceutical tokyo north ryde copenhagen proprietary ltd randburg austria p r ecuador mexico p south korea boehringer ingelheim mexico sa de boehringer ingelheim rcv gmbh boehringer ingelheim del ecuador boehringer ingelheim korea ltd cv mexico city co kg vienna cia ltda quito seoul boehringer ingelheim vetmedica sa forschungsinstitut fr molekulare de cv guadalajara pathologie gesellschaft mbh vienna finland spain p boehringer ingelheim promeco sa viratherapeutics gmbh innsbruck boehringer ingelheim finland ky de cv mexico city boehringer ingelheim espaa sa espoo barcelona belgium netherlands scs boehringer ingelheim commv france sweden boehringer ingelheim bv alkmaar brussels boehringer ingelheim france sas boehringer ingelheim aktiebolag paris stockholm brazil p new zealand boehringer ingelheim brasl great britain boehringer ingelheim nz ltd switzerland r auckland qumica e farmaceutica ltda boehringer ingelheim ltd boehringer ingelheim schweiz paulo bracknell gmbh basel solana agro pecuria ltda arapongas norway amal therapeutic sa geneva greece p boehringer ingelheim norway ks canada boehringer ingelheim ellas ae asker taiwan b oh nr ti onger ingelheim canada ltd athens peru boehringer ingelheim taiwan ltd taipei hong kong boehringer ingelheim peru sac chile boehringer ingelheim hong kong lima thailand v b sao neh tir ai gn og e dr e n cg ill eheim ltda ltd hong kong philippines boehringer ingelheim thai ltd bangkok india boehringer ingelheim philippine china p boehringer ingelheim india private inc manila turkey pb ho aeh rmrin acg ee ur ti cg ae lslh ce oim l ts dh sn hgh aa ni g hai ltd mumbai poland boehringer ingelheim ila ticaret istanbul boehringer ingelheim indonesia p boehringer ingelheim sp z oo biopharmaceutical china co ltd warsaw shanghai pt boehringer ingelheim indonesia usa p r boehringer ingelheim china jakarta portugal boehringer ingelheim investment co ltdshanghai pharmaceuticals inc boehringer ingelheim international israel unilfarmauniao internacional de wilmington delaware laboratrios farmacuticos lda trading shanghai co ltd boehringer ingelheim israel ltd lisbon boehringer ingelheim fremont inc shanghai tel aviv wilmington delaware boehringer ingelheim usa colombia italy p russian federation corporation wilmington delaware ooo boehringer ingelheim moscow boehringer ingelheim sa boehringer ingelheim italia spa vietnam santa f de bogot milan boehringer ingelheim animal health bidachem spa fornovo giovanni vietnam limited liability company ho chi minh city oiloftrop tcudorp boehringer ingelheim annual report consolidate balance sheet asset million eur note intangible asset tangible asset financial asset fix asset inventory account receivable asset cash cash equivalent current asset prepaid expense defer tax asset exceed plan asset total asset equity liability million eur note shareholder capital group reserve balance sheet currency conversion difference equity attributable parent company noncontrolle interest group equity difference capital consolidation provision account payable loan liability defer income defer tax liabillitie total equity liability explanation relevant section note consolidated financial statement consolidate financial statement consolidate balance sheet consolidate profit loss statement consolidated profit loss statement million eur note net sale change finish good work process work capitalize operating income total revenue cost material personnel expense amortization intangible asset depreciation tangible asset operating expense operate income financial income hold income income taxis income taxis income taxis net income noncontrolle interest group profit explanation relevant section note consolidated financial statement legal requirement shareholder personal taxis arise group business activity show withdrawal group reserve oiloftrop tcudorp boehringer ingelheim annual report cash flow statement million eur income taxis include noncontrolle interest amortization reversal writedown intangible asset depreciation reversal writedown tangible asset change provision pension similar obligation include change plan asset change provision noncash income expense gain disposal consolidated company gainloss disposal fix asset grant receive change inventory change account receivable asset relate investing financing activity change trade account payable liability relate investing financing activity interest income interest expense income investment income taxis income taxis pay cash flow operating activity payment aquire intangible fix asset payment aquire tangible fix asset payment aquire financial fix asset payment aquire generate plan asset payment relate purchase price adjustment dispose consolidated entity dispose fix asset investment consolidated company proceed disposal intangible fix asset proceed disposal tangible fix asset proceed disposal financial fix asset proceed disposal consilidate entity interest receive income dividend cash flow investing activity consolidate financial statement cash flow statement statement change group equity cash flow statement million eur cash receipt grant interest pay cash payment shareholder parent company proceed loan cash repayment loan cash flow financing activity change financial fund cash relevant transaction change financial fund change consolidated company change financial fund exchange rate movement financial fund financial fund excl fixedasset investment security cash cash equivalent investment security fix asset source fund use fund statement change group equity balance sheet equity attri currency butable non shareholders group conversion parent control million eur capital reserve difference company interest group equity balance contribution withdrawal net income change consolidate company currency effect balance withdrawal net income currency effect balance shareholder capital consist equity ch boehringer sohn ag co kg ch boehringer sohn grundstcksverwaltung gmbh co kg shareholders capital consist limited partner capital contribution shareholder personal taxis arise group business activity show withdrawal group reserve oiloftrop tcudorp boehringer ingelheim annual report note consolidated financial statement principle method general principle consolidate financial statement boehringer ingelheim financial year prepare accord ance section german commercial code hgb line legal requirement prepare con solidated financial statement section et seq hgb accordance section hgb consolidated financial statement consist consolidated balance sheet consolidated profit loss statement note consolidated financial statement cash flow statement statement change equity consolidated financial statement prepare euro accordance section conjunction section hgb improve clarity transparency consolidated financial statement individual item consoli date balance sheet consolidated profit loss statement combine item present explain separately note additional disclosure require individual item find note registry information parent company register ch boehringer sohn ag co kg headquarters ingelheim rhein commercial register mainz district court number hra information group consolidated companies parent company boehringer ingelheim group ch boehringer sohn ag co kg ingelheim rhein boehringer ag ingelheim rhein sole unlimited partner company boehringer ingelheim group consist total subsidiary germany abroad subsidiary include consolidated financial statement ch boehringer sohn ag co kg con solidation rules ch boehringer sohn grundstcksverwaltung gmbh co kg special purpose entity ch boehringer sohn ag co kg bear majority risk opportunitie economic term ch boehringer sohn ag co kg hold majority voting right subsidiary directly indirectly accordance section hgb subsidiary include consolidation reporting year individually collectively insignificant group net asset financial earning position total sale equity net income year subsidiary include consolidation account aggregated group financial statement total subsidiary ongoing restriction control term article association company con solidate accordance section hgb consolidated financial statement note total number subsidiary decrease compare previous year seven company found company acquire company lose separate legal identity merger affiliated company liquidate company sell follow subsidiary exempt duty prepare disclosure annual financial statement management report accordance section hgb boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim europe gmbh ingelheim rhein boehringer ingelheim secura versicherungsvermittlung gmbh ingelheim rhein boehringer ingelheim grundstcksgmbh ingelheim rhein boehringer ingelheim finanzierung gmbh ingelheim rhein boehringer ingelheim rd beteiligung gmbh ingelheim rhein boehringer ingelheim venture fund gmbh ingelheim rhein boehringer ingelheim invest gmbh ingelheim rhein boehringer ingelheim animal health france participation gmbh ingelheim rhein follow subsidiary exempt duty prepare disclose annual financial statement management report accordance section b hgb ch boehringer sohn ag co kg ingelheim rhein ch boehringer sohn grundstcksverwaltung gmbh co kg ingelheim rhein boehringer ingelheim pharma gmbh co kg ingelheim rhein boehringer ingelheim veterinary research center gmbh co kg hanover boehringer ingelheim participate joint venture company include consolidated financial statement proportionate method equity method material boehringer ingelheim hold interest associate company account equity method lack significance result effect group total asset net income oiloftrop tcudorp boehringer ingelheim annual report consolidation method inventory fix asset receivables liability income expense item transaction company include consolidation eliminate debt consolidation procedure accordance section hgb procedure eliminate intercompany profit accordance section hgb income expense consolidation procedure accordance section hgb acquisition method apply include subsidiary consolidation time accord ance section hgb company include consolidation time date company subsidiary book value share hold parent company offset correspond equity subsid iary equity carry fair value asset liability prepay expense defer income special reserve include consolidated financial statement time consolidation remain ing positive balance record goodwill remain negative balance record difference capital consolidation currency translation asset liability result foreign currency transaction translate average spot exchange rate balance sheet date realization principle section conjunction section halfsentence hgb historical cost convention section conjunction section sentence hgb apply item remain term year consolidated financial statement financial statement foreign subsidiary domicile state eurozone denominate foreign currency convert euro accordance section hgb modify closing date rate method modify closing date rate method asset liability item annual financial statement pre pare foreign currency translate euro average spot exchange rate balance sheet date exception equity translate historical rate item include profit loss statement translate euro average rate result translation difference report consolidated equity reserve balance sheet currency conversion difference exchange rate group important currency change follow report year basis eur spot rate average rate dollar japanese yen chinese renminbi consolidated financial statement note accounting policy fix asset acquire tangible intangible asset carry cost schedule straightline amortization depreciation determine consideration technical economic circumstance base follow useful life goodwill year intangible asset year building year technical facility machine year facility operating equipment year straightline depreciation amortization consolidated financial statement additional writedown record reflect impairment value asset consider permanently impaired manufacturing cost include material labor manufacturing cost appropriate portion materi al labor overhead depreciation fix asset extent cause production manufacturing cost include financing cost capitalize intangible asset finite useful life financial asset primarily include investment security shareholder right loan carry low cost fair market value impair event reason impairment loss recognize previ ous financial year long applicable corresponding reversal record current asset prepay expense defer income exceeding plan asset inventory carry low cost fair market value raw material consumable supply capitalize low average acquisition price fair market value balance sheet date finish good work progress measure manufacturing cost basis individual calculation take account directly attributable cost material direct labor cost special direct cost appropriate share material production overhead cost productionrelate depreciation good resale value lower acquisition cost fair market value oiloftrop tcudorp boehringer ingelheim annual report identifiable risk inventory arise aboveaverage storage period diminish marketability low replacement cost take account record appropriate valuation adjustment inventory value lossfree deduction expect sale price reflect cost incur receivables asset recognize cost allowance specific risk general credit risk lowinter noninterestbeare receivables term year discount cash cash equivalent consist cash balance bank check recognize low cost fair market value prepay expense record accordance section hgb include expense pay advance respect define period time balance sheet date defer income record accordance section hgb include proceed represent income relate define period time balance sheet date fair market value pension plan asset correspond present value pension obligation offset accord german gaap exceeding plan asset capitalize separately difference capital consolidation difference capital consolidation report december primarily result business swap boehringer ingelheim consumer healthcare business sanofis animal health business complete january result difference capital consolidation million eur difference amortize estimate period year remain balance difference amount million eur december difference capital consolidation report december include arise acquisition company original difference amount million eur difference amor tize estimate period year remain balance difference amount million eur december difference capital consolidation primarily influence current year release million eur subsequent purchase price adjustment income release difference arise capital consolidation include operate income release correspond amortization asset acquire company identify purchase price allocation previously recognize compa nys balance sheet consolidate financial statement note group reserve group reserve include retain earning consolidate subsidiary prior current year consolidation entry affect earning provision tax provision provision include uncertain liability expect loss executory contract carry require settle obligation base reasonable prudent commercial judg ment include future cost price increase provision remain maturity year discount matchedterm average market interest rate case pension provision inter est rate result year average market interest rate case provision seven year average market interest rate accordance rckstellungsabzinsungsverordnung german regulation discount provision account payable loan account payable loan recognize settlement defer taxis calculate defer taxis arise temporary quasipermanent difference carry amount asset liability prepay expense defer income group financial statement carry amount tax purpose tax loss carryforward amount result tax benefit expense time difference reverse measure tax rate specific respective consolidated company defer tax balance discount difference consolidation measure accordance section hgb measure companyspecific tax rate applicable time expect reversal difference defer tax asset loss carryforward take account likely year defer tax asset liability report offset oiloftrop tcudorp boehringer ingelheim annual report note consolidated balance sheet intangible asset acquire concession advance million eur similar right goodwill payment total acquisition manufacturing cost balance currency conversion difference change consolidate company addition disposals reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate amortization balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value consolidate financial statement note tangible asset advance technical facility payment land facility operate construction million eur building machine equipment progress total acquisition manufacturing cost balance currency conversion difference change consolidate company addition disposals reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value oiloftrop tcudorp boehringer ingelheim annual report financial asset investment loan investment loan affiliate affiliate relate related investment million eur company companies company company security loan total acquisition manufacturing cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value previous year loan item include loan shareholder consolidated financial statement note inventory million eur raw material supply unfinished good finish good good resale advance payment supplier account receivable asset residual term residual term million eur year year trade account receivable receivables affiliate company receivables related company asset asset item include receivables shareholder million eur previous year half million eur receivable affiliate company exclusively consist receivables loan receivables related company primarily consist trade account receivable provision million eur pension provision similar obligation tax provision provision oiloftrop tcudorp boehringer ingelheim annual report provision pension similar obligation provision pension similar obligation determine basis actuarial calculation project unit credit method take account future adjustment salarie pension addition local biometric datum germany example g mortality table publish prof dr klaus heubeck adjust groupspecific death probability invalidity rate pension obligation significant country calculate basis follow actuarial parameter december germany usa japan discount rate salary increase pension increase discount rate determine reference average market rate year maturity accordance german regulation discount provision march interest rate discount sig nificant foreign pension obligation usa japan determine comparable parameter line german regulation discount provision march difference calculate accordance section hgb amount million eur previous year million eur plan asset intend solely cover pension similar obligation unavailable creditor plan asset define section sentence hgb measure fair market value essentially derive stock market price offset underlie pension similar obligation fair market value plan asset balance sheet date million eur relate pension obligation similar obligation million eur tax provision tax provision include provision double taxation risk result follow implementation action plan organisation economic cooperation development oecd interna tional initiative know action plan base erosion profit shift bep consolidated financial statement note provision provision mainly include provision discount guarantee personnelrelate provision provision outstanding invoice provision litigation legal claim compensation damage account payable loan residual term residual term thereof million eur year year year year bank loan account payable thereof trade account payable advance payment receive account payable affiliate company account payable relate company liability thereof taxis million eur social security liability million eur previous year liability secure mortgage similar collateral right balance sheet date end year liability shareholder million eur previous year million eur present liability item account payable affiliate company include loan amount million eur previous year million eur trade account payable amounting million eur previous year million eur oiloftrop tcudorp boehringer ingelheim annual report note consolidated profit loss statement structure consolidated profit loss statement base total cost format taxis include operating expense provide well view earning position cost material partially reclassify operating expense previous year figure adjust million eur well comparability net sale business million eur human pharma animal health biopharmaceutical contract manufacturing sale discontinue operation region million eur americas europe asiaaustraliaafrica aaa operating income operating income include income currency translation million eur previous year million eur cost material million eur cost raw material supply good resale expenditure service consolidate financial statement note personnel expense million eur wage salarie social benefit retirement benefit thereof retirement benefit interest effect measurement provision pension similar obligation show separate item financial income average headcount production marketing sale research development administration apprentice methodology calculate average number employee revise consolidated finan cial statement calculate average originally base previous endofquarter figure change assessment base monthend figure figure adjust line new methodology result overall difference employee amortization intangible asset depreciation tangible asset amortization intangible asset depreciation tangible asset include impairment loss mil lion eur previous year million eur operating expense operating expense include expense currency translation million eur previous year million eur addition item include operating expense mainly charge record provision legal risk restructure thirdparty service research development medicine marketing purpose administrative expense fee contribution commission rent freight expense repair carry party oiloftrop tcudorp boehringer ingelheim annual report financial income million eur interest result provision pension similar obligation provision interest expense similar expense interest expense similar expense amortization loss disposal financial fix asset shortterm investment income investment security longterm loan interest income similar income gain loss plan asset interest expense relate pension similar obligation offset accordance section sentence hgb total million eur earning plan asset million eur interest expense relate pension similar obligation include interest result provi sion pension similar obligation provision hold income million eur writedown financial asset writeup financial asset income relate company thereof disposal relate company income taxis million eur current income taxis defer taxis current income taxis primarily include corporation trade tax expense consolidated company total balance defer tax asset balance sheet date amount million eur previous year million eur defer tax asset primarily arise difference carry amount provision pension obligation discount tax goodwill intangible asset inventory tangible asset defer tax liability million eur previous year million eur record primarily relate difference carry amount intangible asset tangible asset inventory provision consolidated financial statement note net income net income positively influence nonperiod income primarily reversal provision million eur previous year million eur negatively influence nonperiod expense mainly taxis previous year million eur previous year million eur note cash flow statement cash flow statement show change cash cash equivalent cash longterm investment security sell time boehringer ingelheim group result cash inflow outflow report year accordance german accounting standard cash flow statement dr cash flow statement break accord cash flow operating activity cash flow invest ing financing activity change balance sheet item affiliate company include translate average rate year balance sheet cash cash equivalent carry spot rate effect exchange rate change cash cash equivalent show separately financial fund include financial asset remain maturity exceed month date acquisition financial asset convert cash shortterm financial fund december comprise follow item million eur cash cash equivalent financial asset financial fund include million eur restrict fund balance sheet date oiloftrop tcudorp boehringer ingelheim annual report disclosure contingent liability million eur liability guarantee warranty grant security thirdparty liability risk utilization contingent liability assess low account good net asset financial earning position financial commitment offbalance sheet transaction million eur rental lease obligation residual financial commitment thereof pensionrelate obligation rental lease agreement million eur previous year million eur million eur previous year million eur relate longterm rental agreement nonconsoli date subsidiary purpose lease agreement low capital commitment compare buy property absence resale risk risk arise term lease possible continue utilize property fully indication time residual financial commitment include future capital expenditure million eur previous year million eur derivative financial instrument valuation unit extensive international structure boehringer ingelheim group highly dependent development world currency interest rate hedge risk particularly emerge delivery good service finance currency forwards option generally currency risk interest rate swap option interest rate risk use derivative financial instrument organizational process set internal guideline strict separation trading processing documentation control consolidated financial statement note risk position regularly track analyzed measure special groupwide financial report position enter periodically reevaluate monitor fair value derivative financial instrument calculate generally accept market valuation method currency forward base present value method take account market datum balance sheet date provision million eur recognize currency forward include hedge accounting negative fair value currency balance sheet date line imparity principle positive fair value currency recognize balance sheet date derivative financial instrument include hedge accounting valuation unit follow nominal value fair value million eur foreign exchange forward contract extent requirement hedge account foreign currency forward exchange contract highly probable forecast transaction accordance section hgb meet foreign currency forward exchange contract recognize balance sheet line net hedge presentation method follow accounting policy apply recognition valuation unit accordance section hgb economic hedge account financial statement use valuation unit valuation unit recognize foreign currency base net highly probable forecast transaction currency forwards match forecast net cash flow term maturity nominal foreign currency macro hedge highly probable forecast transaction income outgoing payment plan sale pur chase derive company plan expost analysis planning show plan transaction highly probable oppose change value hedge item hedge instrument fully offset critical term maturity nominal foreign currency match effective hedge assume prospectively retrospectively critical term match method exclusively measure prospective retrospective effectiveness hedge excess amount hedging transaction include valuation unit oiloftrop tcudorp boehringer ingelheim annual report december hedge highly probable forecast net cash flow recognize follow january december net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd jpy jpy jpy consolidated financial statement note january february net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd jpy jpy jpy furthermore december valuation unit foreign currency receivable recognize follow receivables million eur foreign exchange forward contract million eur nominal value nominal value fair value rub rub rub pln pln pln hedge foreign currency risk correlate relative change exchange rate planning date realization date forecast transaction currency appreciate depreciate euro foreign currency risk million eur hedge research development expense million eur research development expense noncapitalized research development expense include item cost associate clinical study total auditor fee total fee charge group auditor financial year amount million eur million eur relate audits financial statement million eur assurance service million eur tax advisory service million eur service oiloftrop tcudorp boehringer ingelheim annual report subsequent event december asset purchase agreement sign hypera sa boehringer ingelheim sale buscopan business brazil agreement contain condition closing execution asset sale include antitrust authority approval relevant condition transaction expect conclude financial year equivalent approximately million eur bal ance sheet date agree selling price end financial year aware event material signif icance group lead reappraisal net asset financial earning position shareholding list company include consolidated financial statement complete list shareholding present accordance section hgb include audit consolidated financial statement submit german federal gazette ingelheim rhein march boehringer ag board manage director hubertus von baumbach carinne knochebrouillon dr michel pairet jean scheftsik de szolnok michael schmelmer independent auditor report independent auditor report ch boehringer sohn ag co kg ingelheim rhein qualified audit opinion consolidated financial statement audit opinion group manage ment report audit consolidated financial statement ch boehringer sohn ag co kg ingelheim rhein subsidiary group comprise consolidated balance sheet december consolidated profit loss statement cash flow statement statement change group equity finan cial year january december note consolidated financial statement include sum mary significant accounting policy addition audit group management report ch boehringer sohn ag co kg financial year january december opinion basis knowledge obtain audit effect matter describe section basis qualified audit opinion consoli date financial statement audit opinion group management report accompany consol idate financial statement comply material respect requirement german commercial law true fair view asset liability financial position group december financial performance financial year january december accordance german legally require accounting principle accompany group management report provide appropriate view group position material respect group management report consistent consolidated financial statement complie german legal requirement appropriately present opportunity risk future devel opment pursuant section sentence hgb handelsgesetzbuch german commercial code declare qualification audit opinion consolidated financial statement mention audit lead reservation relate legal compliance consolidated financial statement group management report basis qualified opinion consolidated financial statement audit opinion group management report contrary section number letter b hgb total remuneration grant member member board manage director pension provision recognize recog nize member board manage director disclose note consolidated financial statement conduct audit consolidated financial statement group management report accord ance section hgb german generally accept standard financial statement audits promul gate institut der wirtschaftsprfer institute public auditor germany idw responsibility requirement principle describe auditor responsibility audit consolidated financial statement group management report section auditor report independent group entity accordance requirement german commercial professional law oiloftrop tcudorp boehringer ingelheim annual report fulfil german professional responsibility accordance requirement believe evidence obtain sufficient appropriate provide basis opinion consolidate financial statement group management report information management responsible information information comprise annual report exception audit consolidated financial statement group management report auditor report opinion consolidate financial statement group management report cover information consequently express opinion form assurance conclusion thereon connection audit responsibility read information consider information materially inconsistent consolidated financial statement group management report knowledge obtain audit appears materially misstate responsibility management consolidated financial statement group management report management responsible preparation consolidate financial statement comply material respect requirement german commercial law consolidated financial statement true fair view asset liability financial position financial performance group compliance german legally require accounting principle addition management responsible internal control accordance german legally require accounting principle determine necessary enable preparation consolidated financial statement free material misstatement fraud error prepare consolidated financial statement management responsible assess group ability continue go concern responsibility disclose applicable matter relate go concern addition responsible financial reporting base go concern basis accounting provide actual legal circumstance conflict therewith furthermore management responsible preparation group management report pro vide appropriate view group position material respect consistent consolidated financial statement complie german legal requirement appropriately present opportunity risk future development addition management responsible arrangement measure sys tem consider necessary enable preparation group management report accord ance applicable german legal requirement able provide sufficient appropriate evidence assertion group management report independent auditor report auditor responsibility audit consolidated financial statement group manage ment report objective obtain reasonable assurance consolidated financial statement free material misstatement fraud error group management report provide appropriate view group position material respect consistent con solidated financial statement knowledge obtain audit complie german legal require ment appropriately present opportunity risk future development issue auditor report include opinion consolidate financial statement group management report reasonable assurance high level assurance guarantee audit conduct accordance section hgb compliance german generally accept standard financial statement audits promulgate institut der wirtschaftsprfer idw detect material misstatement misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis consolidated financial state ment group management report exercise professional judgement maintain professional scepticism audit identify assess risk material misstatement consolidated financial statement group management report fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit consolidate financial statement arrangement measure system relevant audit group management report order design audit procedure appropriate circumstance purpose express opinion effectiveness system evaluate appropriateness accounting policy management reasonableness estimate management relate disclosure conclude appropriateness management use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt group ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure consolidate financial statement group management report disclosure inadequate modify respective opinion conclusion base audit evidence obtain date auditor report future event condition cause group cease able continue go concern evaluate overall presentation structure content consolidated financial statement include disclosure consolidated financial statement present underlying transaction event manner consolidated financial statement true fair view asset liability financial position financial performance group compliance german legally require accounting principle oiloftrop tcudorp boehringer ingelheim annual report obtain sufficient appropriate audit evidence financial information entity business activ itie group express opinion consolidate financial statement group manage ment report responsible direction supervision performance group audit remain solely responsible opinion evaluate consistency group management report consolidate financial statement conformity german law view group position provide perform audit procedure prospective information present management group management report basis sufficient appropriate audit evidence evaluate particular significant assump tion management basis prospective information evaluate proper derivation prospective information assumption express separate opinion prospective infor mation assumption basis substantial unavoidable risk future event differ materially prospective information communicate charge governance matter plan scope time audit significant audit finding include significant deficiency internal control identify audit frankfurt main march kpmg ag wirtschaftsprfungsgesellschaft original german version sign kneisel krau wirtschaftsprfer wirtschaftsprfer german public auditor german public auditoroiloftrop tcudorp page p r u c p r f l e l e c n human pharmaceutical animal health boehringer ingelheim annual report respiratory disease respiratory disease common chronic obstructive bronchial asthma pulmonary disease copd bronchial asthma bronchial asthma chronic inflammatory disorder prevalent chronic disease frequent cause airways inflammation accompany airway hyper morbidity premature death worldwide responsiveness lead narrow airways recurrent episode wheeze breathlessness cough idiopathic pulmonary fibrosis ipf rare disease symptom occur particularly night early severely debilitate ultimately lethal hour morning know asthma trig gere genetic environmental factor eg allergen copd viral infection unlike copd asthma occur early copd chronic disease lung cause cough childhood present adolescent adults excessive mucus production dyspnea ultimately asthma underestimate easytomanage condi destroy lung tissue alveolus gas exchange tion patient asthma affect lead limitation airflow cause experience symptom receive maintenance therapy shortness breath respiratory symptom air put increase risk potentially lifethreatene flow limitation partially reversible usually worsen asthma exacerbation addition patient adjust time lead disability ultimately death symp daily life accommodate condition avoid physical tom excess cough breathlessness main exertion daytoday activity negative impact reason copd stressful patient lung emphy quality life sema chronic bronchitis main manifestation copd copd cause continuous damage lung result inhale pollutant primarily cigarette smoke factor need consider include indoor outdoor air pollution course copd disease occur second half human life character ize accelerate loss lung function compare mal age occasional sudden worsen symptom function refer acute exacerbation lead downward spiral worsen symptom inactivity product portfolio human pharmaceutical indication brand name active ingredient chronic obstructive spiriva tiotropium bromide maintenance treatment patient copd pulmonary disease copd spiriva handihaler include chronic bronchitis emphysema spiriva respimat maintenance treatment associate dyspnoea prevention exacerbation bronchial asthma spiriva respimat tiotropium bromide addon maintenance bronchodilator treat ment patient age year old severe asthma experience severe asthma exacerbation past year spiriva respimat approve use asthma eu japan usa country label vary country refer local product information chronic obstructive spiolto respimat tiotropium bromide maintenance treatment airflow obstruction pulmonary disease copd stiolto respimat olodaterol hydrochloride patient chronic obstructive pulmonary inspiolto respimat disease copd c hronic obstructive striverdi respimat olodaterol hydrochloride maintenance treatment patient chronic pulmonary disease copd obstructive pulmonary disease copd reversible bronchospasm combivent respimat ipratropium bromide combination shortacte anticholinergic associate obstructive salbutamol sulphate betaadrenergic management airway disease reversible bronchospasm associate obstructive airway disease patient requir e bronchodilator c hronic obstructive atrovent ipratropium bromide prevention treatment shortness pulmonary disease copd breath patient chronic obstructive chronic bronchitis pulmonary disease copd mild moder bronchial asthma eat bronchial asthma adulthood child hood supplement betaagonist case acute asthma c hronic obstructive airway berodual ipratropium bromide prevention treatment symptom disorder bronchodual fenoterol hydrobromide chronic obstructive airway disorder duovent reversible airflow limitation bronchial asthma especially chronic bronchitis emphysema boehringer ingelheim annual report respiratory disease continue idiopathic pulmonary fibrosis ipf systemic sclerosis associate interstitial lung ipf chronic progressive lung disease associate disease sscild markedly reduce life span affect systemic sclerosis ssc know scleroderma rare people worldwide ipf characterize progre incurable autoimmune disease affect connective tissue sive scar lung tissue loss lung function disease estimate affect people time development scarred tissue call fibrosis europe million worldwide ssc impact time time tissue thicken stiffen scar lung woman man onset disease typically lose ability transfer oxygen blood occur young age year cause stream vital organ oxygen result scar fibrosis skin major organ individual ipf experience shortness breath heart lung digestive tract kidney rest difficulty cope demand lifethreatene complication approximately patient everyday life limited physical capacity develop significant pulmonary involvement year diagnosis ssc affect lung cause intersti acute ipf exacerbation define rapid deterioration tial lung disease ild know sscild key driver symptom lung function day week mortality people ssc accounting approxi event occur point course disease mately death presentation associate high mortality patient ipf risk acute ipf exacerbation product portfolio human pharmaceutical indication brand name active ingredient bronchial asthma berotec fenoterol hydrobromide symptomatic treatment acute asthma attack prophylaxis exerciseinduce asthma bron chiale symptomatic treatment allergic non allergic asthma bronchiale condition reversible airway narrow eg chronic obstructive bronchitis bronchial asthma alesion epinastine hydrochloride prophylactic treatment patient bron allergic rhinitis flurinol chial asthma prophylaxis symptomatic treatment allergic rhinitis diopathic pulmonary fibrosis ofev nintedanib treatment patient idiopathic pulmo ipf nary fibrosis ipf ystemic sclerosis associate approve usa brazil canada japan interstitial lung disease country therapy sscild slow sscild rate decline pulmonary function boehringer ingelheim annual report cardiovascular metabolic disease cardiovascular cv disease leading cause death prevention treatment venous worldwide increase prevalence currently thromboembolism responsible nearly death worldwide key venous thromboembolism vte umbrella term risk factor develop cardiovascular disease pre encompasse deep vein thrombosis dvt pulmonary ence diabete people type diabete embolism pe dvt occur thrombus blood clot form time likely develop cardiovascular disease peo deep vein commonly leg partially com ple diabete result life expectancy pletely blocks flow blood thrombus grow por year short proper control diabete treat tion break away main clot travel circu able risk factor vital prevention cardio latory system lung lodge blood clot vascular event artery lung call pe vte disorder potentially fatal consequence stroke stroke rapidly develop loss brain function cause patient undergo orthopedic surgery considerable disrupt blood flow affect brain tissue risk develop dvt chronic venous insufficiency ischemia lack blood supply cause thrombo pulmonary hypertension develop long term sis embolism bleed hemorrhagic stroke prevent vte event consequence orthopedic result affect area brain unable function surgery patient receive kind thromboprophy damage quickly permanent untreated stroke laxis patient suffer vte require anti acute event require emergency diagnosis interven coagulant treatment secondary prevention recurrent tion worldwide stroke lead cause death thromboembolic event longterm disability reverse anticoagulation symptom transient ischemic attack tia similar anticoagulation therapy offer important benefit patient stroke minute hour risk thromboembolic event rare result permanent neurological damage tia pre situation rapid reversal anticoagulation cede stroke emergency medical care subsequent pre medically necessary eg patient take anticoagulant ventive treatment necessary involve severe car accident need emergency surgery atrial fibrillation atrial fibrillation af common sustained heart rhythm condition affect approximately total pop ulation adult develop af lifetime patient af high risk develop blood clot upper leave heart chamber cause stroke clot break loose travel brain af lead fivefold increase risk stroke result million patient worldwide suffer afrelate stroke year patient af risk stroke reduce appropri eat anticoagulation therapy product portfolio human pharmaceutical indication brand name active ingredient stroke prevention atrial pradaxa dabigatran etexilate prevention stroke blood clot fibrillation pradaxar patient atrial fibrillation primary prevention venous prazaxa primary prevention venous thromboembolic thromboembolic event event vte adult elective total hip orthopedic surgery knee replacement surgery treatment secondary prevention venous treatment deep vein thrombosis dvt thromboembolic event pulmonary embolism pe secondary prevention recurrent dvt pe adult pecific reversal pradaxa praxbind idarucizumab praxbind specific reversal agent dabigatran etexilate dabigatran indicate adult patient treat pradaxa dabigatran etexilate rapid reversal anticoagulant effect require emergency surgeryurgent procedure lifethreatene uncontrolled bleed hypertension micardis telmisartan treatment hypertension reduction c ardiovascular morbidity risk myocardial infarction heart attack mortality prevention stroke death cardiovascular cv cause patient year age old high risk develop major cv event unable ace inhibitor reduction cardiovascular morbidity patient manifest atherothrombotic car diovascular disease history coronary heart disease stroke peripheral arterial disease patient type diabete mellitus document target organ damage eu hypertension micardisplus telmisartan treatment hypertension micardi plus hydrochlorothiazide antihypertensive agent low blood pre micardis hct sure lower blood pressure reduce risk comicardi fatal nonfatal cardiovascular event primarily stroke myocardial infarction indicate initial therapy treatment essential hypertension micardisplus fix dose combination indicate adult blood pressure adequately control telmisartan eu boehringer ingelheim annual report cardiovascular metabolic disease continue hypertension cardiovascular disease hypertension high blood pressure chronic disease blood pressure chronically elevated hypertension major risk factor stroke heart attack heart failure chronic renal failure primary goal anti hypertensive treatment prevent cardiovascular event reduce risk cardiovascular mortality acute myocardial infarction acute myocardial infarction heart attack occur thrombus blood clot suddenly prevent blood flow area heart muscle blood flow restore quickly affect section heart muscle permanently damage heart attack common cause death industrialize country product portfolio human pharmaceutical indication brand name active ingredient hypertension twynsta telmisartan amlodipine treatment hypertension micamlo antihypertensive agent initial therapy micardi amlo patient likely need multiple antihypertensive micardi duo agent achieve blood pressure goal addon therapy adult patient ade quately control blood pressure amlodip ine replacement therapy adult patient receive telmisartan amlodipine separate tablet eu acute ischemic stroke actilyse alteplase fibrinolytic treatment acute ischemic stroke acute myocardial infarction actilyse cathflo acute myocardial infarction acute massive cute massive pulmonary pulmonary embolism fibrinolytic treatment embolism occlude catheter c atheter clearance thrombotic occlusion econdary prevention aggrenox dipyridamole prevention stroke follow initial stroke transient ischemic asasantin acetylsalicylic acid stroke transient ischemic attack tia attack tia asasantin retard acute myocardial infarction metalyse tenecteplase fibrinolytic treatment acute myocardial infarction hypertension catapresan clonidine treatment hypertension catapre clonidine hydrochloride catapressan boehringer ingelheim annual report cardiovascular metabolic disease continue diabete addition cardiovascular disease complication type diabetes chronic progressive condition associate diabete include elevate blood sugar level cause longterm complication treat estimate million death nephropathy culminate renal failure require dialysis worldwide year link directly longterm retinopathy potential loss vision effect diabete type diabete common form peripheral neuropathy risk develop foot ulcer disease account case potentially require foot leg amputation develop world currently million people autonomic neuropathy cause gastrointestinal world live diabetes represent enormous genitourinary cardiovascular symptom sexual dys burden health care system globally effective pre function vention management strategy estimate number case reach million addition type diabete major risk factor cardiovascular disease life expectancy people type diabete high cardiovascular risk decrease average year overall half death people type diabete cause concomitant cardiovascular dis ease indicate high unmet medical need product portfolio human pharmaceutical indication brand name active ingredient type diabete mellitus trajenta linagliptin treatment adult type diabete tradjenta mellitus adjunct diet exercise trazenta improve glycemic control monotherapy trayenta metformin tolerate contraindi cat combination therapy type diabete mellitus jentadueto linagliptin metformin treatment adult type diabete trayenta duo hydrochloride mellitus adjunct diet exercise trajenta duo improve glycemic control treatment trajentamet metformin lead sufficient control patient treat trajenta linagliptin metformin type diabete mellitus jardiance empagliflozin treatment adult type diabete melli jardianz tus adjunct diet exercise improve glycemic control reduce risk cardiovascular death adult type diabete mellitus establish cardiovascu lar disease indication december label vary country refer local product information type diabetes mellitus synjardy empagliflozin treatment adult type diabete melli jardiance duo metformin tus adjunct diet exercise improve hydrochloride glycemic control treatment empagliflozin metformin appropriate indication december label vary country refer local product information type diabete mellitus glyxambi empagliflozin linagliptin treatment adult type diabete melli tus adjunct diet exercise improve glycemic control adult type diabete mellitus empagliflozin linagliptin appropriate treatment indication march label vary country refer local product information diabete portfolio collaboration eli lilly company boehringer ingelheim annual report oncology cancer threat global health estimate different subtype small cell lung cancer million new case cancer diagnose worldwide sclc nonsmall cell lung cancer nsclc million people die cancer nearly global different molecular genetic aberration mutation present death world cancer factsheet com tumor identify focus molecular mon diagnose cancer type lung cancer nearly change specific respective subtype lung breast cancer nearly colorectal cancer prostate cancer target therapy effective cancer stomach cancer treatment survival benefit time harmful normal cell reduce lung cancer effect lung cancer refer malignant abnormal cell growth inside lung tissue common cancer esti mate million new case year worldwide smok e primary cause disease contribute case recently incidence lung cancer nonsmoker increase lung cancer poor prognosis million death year represent nearly cancer death lung cancer symptom unspecific disease year appear late diagnosis advanced stage disease result dismal prognosis lung cancer patient survive year follow diagnosis product portfolio human pharmaceutical indication brand name active ingredient nonsmall cell lung cancer giotrif afatinib firstline treatment adult patient locally nsclc gilotrif advanced metastatic nonsmall cell lung cancer nsclc tumor activate epidermal growth factor receptor egfr mutation treatment patient locally advanced metastatic nsclc squamous histology progressing platinumbase chemotherapy n onsmall cell lung cancer vargatef nintedanib combination therapy docetaxel nsclc treatment adult patient locally advanced metastatic locally recurrent nonsmall cell lung cancer nsclc adenocarcinoma tumor histology firstline chemotherapy boehringer ingelheim annual report disease central nervous system mental neurological disease depression associate pd depression sleep disorder parkinson disease significantly impact patient primary symptom result lack neuro family substantial burden society transmitter dopamine distinct area human brain parkinson disease restless leg syndrome rls parkinson disease pd degenerative disorder cen restless leg syndrome rls common neurological disor tral nervous system patient usually notice motor symptom der characterize uncontrollable urge leg like hand shake tremor sign disease primarily occur evening night hour usually progress include shake arm leg accompany unpleasant painful sensa head motor symptom develop time tion leg disturb sleep result daytime include stiffness result loss facial expression tiredness sleepiness sensation feel deep gradual slow loss motion freeze leg describe creep crawl ache patient suffer nonmotor symptom infectious disease hiv infectionaid acquire immune deficiency syndrome aid set symp tom infection result damage human immune system cause human immunodeficiency virus hiv untreated infection hiv progressively reduce effectiveness immune system leave individual sus ceptible opportunistic infection tumor baby infect mother risk get virus preg nancy childbirth breastfeed product portfolio human pharmaceutical indication brand name active ingredient parkinson disease pd sifrol pramipexole symptomatic treatment idiopathic restless leg syndrome rls mirapex parkinson disease mono mirapexin therapy combination levodopa pexola symptomatic treatment idiopathic moderate severe restless leg syndrome sleep disorder lendormin brotizolam shortterm treatment disorder initiate maintain sleep insomnia require pharmacological inter vention indication brand name active ingredient hivaid viramune nevirapine combination therapy hiv infection viramune xr country prevention mothertochild transmission hiv preg nant woman take antiretroviral therapy time labor prolong release tablet oncedaily dose combination therapy hivaids aptivus tipranavir indicate combination antiretroviral treat ment hivinfecte patient coadmini tere mg ritonavir treat mentexperience infect hiv strain resistant protease inhibitor boehringer ingelheim annual report livestock swine infectious respiratory disease infectious enteric disease ingelvac circoflex singledose piglet vaccine enterisol ileitis oral live vaccine control porcine circovirus disease pcvd vaccine ileitis globally prevalent enteric disease swine provide significant reduction mortality acute phase cause lawsonia intracellularis license improve pcvd improve growth rate chronic phase weight gain reduce growth variability associate disease ingelvac circoflex protect minimal disease enterisol ileitis help reduce total anti systemic adverse reaction injection site swelling microbial use pork production gestation lactation ingelvac prrs product license active immunization respiratory reproductive form porcine reproductive respiratory syndrome prrs ingelvac mycoflex provide proven safety efficacy rapid onset longlaste immunity mycoplasma hyo pneumoniae hyo single dose ingelvac mycoflex contain impranflex adjuvant allow fresh mix ingelvac circoflex form flexcombo ingelvac provenza protect multiple iavs strain decrease nasal shed provide protection pig vulnerable product portfolio animal health indication brand name active ingredient infectious respiratory ingelvac circoflex recombinant vaccine active immunization pig disease porcine circovirus age week porcine circovirus type pcv type reduce mortality clinical sign include weight loss lesion lymphoid tissue associate porcine circovirus disease pcvd addition vaccination show reduce pcv nasal shed viral load blood lymphoid tissue duration viremia infectious respiratory ingelvac prrs mlv attenuate live vaccine depend product active disease ingelvac prrsflex eu prrs virus type type immunization pig age reprocyc prrs eu porcine reproductive respiratory syndrome virus prr infectious respiratory ingelvac mycoflex inactivate vaccine active immunization pig disease mycoplasma age week reduce lung lesion hyopneumoniae follow infection mycoplasma hyo pneumoniae infectious respiratory ingelvac provenza attenuate live influenza vaccine vaccination pig day age disease laiv old influenza virus strain hn hn infectious enteric disease enterisol ileitis attenuate live vaccine active immunization pig lawsonia intracellularis age week intestinal lesion cause lawsonia intracellularis infection reduce growth variability loss weight gain associate disease boehringer ingelheim annual report livestock cattleruminant cattleruminant business global leader antiparasitic brand ivomec longrange eprinex world renowne parasiticide treat protect graze animal harmful effect internal external parasite zactran treat cattle bacterial pneumonia sheep digital dermatitis infection bovela active immunization cattle month age term reproductive infectious disease product portfolio animal health indication brand name active ingredient internal external ivomec ivermectin depend formulation product parasite cattle treatment nematode lice mite tick fly lungworm liver fluke nternal external longrange eprinomectin longacting theraphase technology develop parasite cattle formulation eprinomectin allow single treatment day long break parasite life cycle effectively reduce parasite burden pasture longrange effective con trol internal external parasite cattle gastrointestinal roundworm lung worms grub mite nternal external eprinex eprinomectin depend formulation product parasite ruminant treatment nematode lice mite tick fly lungworm cattle sheep bacterial cause respiratory zactran gamithromycin depend species indication country disease interdigital registration product treat dermatitis footrot ment metaphylaxis control respiratory disease cattle cause key bacteria mannheimia pasteurella histophilus mycoplasma footrot disease sheep cause key bacteria fusobacterium dichelobacter reproductive infectious bovela bovine viral diarrhoea bvd reduce hyperthermia minimize disease cattle type reduction leukocyte count cause bovine viral diarrhoea virus bvdv bvdv reduce virus shed viremia cause bvdv prevent birth persistently infect calf cause transplacental infection boehringer ingelheim annual report livestock cattleruminant continue vaccine pyramidpresponse expand portfolio respiratory reproductive vaccine prevent disease affect livestock metacam nonsteroidal antiinflammatory drug nsaid help minimize loss inflammation tissue damage animal suffer disease address need maintain profitability concern farm animal wellbee product portfolio animal health indication brand name active ingredient infectious respiratory pyramid family multivalent vaccine combina pyramidpresponse family vaccine disease reproductive presponse tion include different modify live provide broad coverage bvd type disorder cattle virus bovine viral diarrhoea bvd ibr brsv pi mannheimia haemolytica type infectious bovine rhino single dose contain tracheitis ibr parainfluenza pi metastim adjuvant system enhance bovine respiratory syncytial virus animal response great protection brsv bacteria pasteurella canada multocida mannheimia haemolytica metastim registered trademark l canicola l grippotyphosa l hardjo zoetis services llc l icterohaemmorrhagiae l pomona pain inflammatory metacam meloxicam treatment mastitis lactate cow disorder control pain associate dehorning surgery indicate use calf affect diarrhoea cattle suffer respiratory disease boehringer ingelheim annual report livestock poultry poultry vaccine portfolio consist significant range live inactivate vaccine broiler layer breeder hen provide protection critical viral bacterial disease like avian influenza infectious bronchitis newcastle disease infectious bursal disease egg drop syn drome avian coryza portfolio preventive product help producer worldwide provide safe affordable abun dant sustainable highquality poultry meat egg product portfolio animal health indication brand name active ingredient viral bacterial gallimune polyvalent attenuate live inacti vaccination healthy chicken disease poultry gallivac vate vaccine contain antigen disease caused include antigen volvac vaccination avian influenza prevention common disease newcastle disease avian broiler chicken disease responsible coryza egg drop syndrome loss egg production layer infectious bronchitis infectious bursal disease gallibacterium anatis infectious bursal disease vaxxitekhvt ibd serotype live marek disease vector prevent mortality reduce clinical marek disease live vhvt recombinant virus sign lesion infectious bursal disease diluent onset protection week protection extend week reduce mortality clinical sign lesion marek disease onset protection day single vaccination sufficient provide reliable protection risk period infectious bursal newcastle vaxxitek hvt ibd ndbursal disease marek disease new vaccination dayold embryos marek disease castle disease vaccine serotype onedayold chicken effective live marek disease vector vaccine standard variant infectious bursal new contain gene ibd ndv castle marek disease diluent newcastle disease nd avinew live newcastle disease virus broiler chicken day age active vggaavinew strain immunization newcastle disease reduce mortality clinical sign associate disease future layer future breeder pullet age week prime active immunization egg drop cause newcastle disease vaccination inactivated vaccine strain ulster c prior beginning lie marek disease prevexxiontm rn live herpe virus chimera vaccine recommend ovo serotype strain rn vaccination dayold embryonate diluent chicken egg protect virulent marek disease newcastle marek newxxitektm hvt nd live marek disease vectore vaccination dayold embryos disease virus serotype onedayold chicken effective contain gene insert marek disease newcastle disease newcastle disease diluent boehringer ingelheim annual report veterinary public health vph work government private partner rabisin inactivated vaccine rabie available improve control eradicating disease footand clear colorless suspension injection mouth disease bluetongue virus rabie btv pur multistrain vaccine active immunization footandmouth vaccine portfolio work active sheep cattle prevent viremia reduce clinical immunization cattle sheep pig reduce clinical sign sign cause bluetongue virus mortality follow exposure footandmouth disease fmd virus product portfolio animal health indication brand name active ingredient footandmouth disease aftopor mix inactivated fmd virus antigen fmd vaccine highly potent purify fmd aftovaxpur wide range vaccine antigen aftopor aftovaxpur aftobov aftovax strain oleosa potential marker property aftobov oleosa allow differentiation infect aftovaxpur doe vaccinate animal diva endemic emergency situation aftovaxpur doe suitable emergency situation rabie rabisin rabisin inactivated adjuvanted rabisin active immunization raboral vrg rabie glycoprotein raboral vrg dog cat reduce mortality clini vaccinavectore rabie vaccine cal sign rabie infection immunity demonstrate month vaccina tion show persist revaccination dose raboral vrg oral rabie recombinant vaccine protect raccoon coyote rabie reduce risk exposure rabie human domestic animal sell government agen cie conduct rabie control program bluetongue btv pur mix inactivated bluetongue virus active immunization sheep prevent viremia reduce clinical sign cause bluetongue virus serotype andor combination maximum serotype active immunization cattle prevent viremia cause bluetongue virus serotype andor reduce clinical sign cause bluetongue virus serotype andor combination maximum serotype onset immunity demonstrate week week sheep btv primary vaccination course btv btv cattle btv btv serotype boehringer ingelheim annual report companion animal horse main equine product focus prevention treat eqvalanzimecterin contain ivermectin lead ingredi ment parasite infestation management solution ent control wide variety important internal parasite chronic disease gastric ulcer vaccine equine port include bot benzimidazoleresistant small strongyle folio include range flagship product treat easytoadminister oral paste eqvalanzimecterin ment joint disease colic respiratory disease approve adult horse foal young week line nutraceutical age prascend indicate treatment pituitary par eqvalan duogold zimecterin gold combine ivermectin intermedia dysfunction ppid know equine praziquantel ingredient specifically control tape cushing disease clinical sign ppid hypertrichiosis worm laminitis change body conformation lack perfor mance treatment prascend lifelong articell forte world license veterinary stem cell product readytouse intraarticular injection vetera vaccine vaccine portfolio include chondrogenic induced mesenchymal cell treatment multiple convenient combination disease protection lameness horse articell forte late addi horse young month age vaccine pro tion equine portfolio available range tect infectious organism include country eu influenza herpe west nile virus tetanus enable customise protection horse limited aservo equihaler inhalation product needle injection treatment severe equine asthma product novel glucocorticoid prodrug ciclesonide inhalation solution gastrogardulcergard indicate treatment deliver inhaler specifically design use horse prevention equine gastric ulcer implement soft mist technology derive common disease horse gastrogard supply respimat inhaler human pharma exciting new intro easytouse oral paste form choice duction gain final authorization product availability treatment gastric ulcer launch ulcergard eu early approval country usa preventive choice horse expect course increase risk develop gastric ulcer product portfolio animal health indication brand name active ingredient pituitary par intermedia prascend pergolide mesylate symptomatic treatment clinical sign dysfunction ppid associate pituitary par intermedia dysfunction ppid know equine cushing disease combination vaccine vetera eastern western venezuelan vaccination healthy horse aid common disease encephalomyelitis tetanus west nile prevention disease cause horse virus equine herpe virus equine include antigen canada influenza viruse equine gastric ulcer gastrogard omeprazole treatment prevention gastric ulcer ulcergard prevention recurrence gastric ulcer horse foal week age old internal parasite eqvalan ivermectin treatment prevention parasitic zimecterin ivermectin praziquantel infestation horse donkey eqvalan gold large small strongyle ascarids eqvalan duo goldduo include treatment zimecterin gold tapeworm reduction mild articell forte chondrogenic induce equine treatment mild moderate lameness moderate recurrent lameness allogeneic peripheral bloodderive link noninfective joint inflammation associate nonseptic mesenchymal stem cell horse contain stem cell joint inflammation horse obtain equine blood stem cell develop type cell stem cell active substance mesenchymal stem cell treat develop cartilage cell severe equine asthma aservo equihaler ciclesonide inhalation solution alleviation clinical symptom severe equine asthma characterize cough nasal discharge nasal flare increase breathing effort rest abnormal lung sound articell forte register trademark global stem cell technology boehringer ingelheim annual report companion animal pet pet portfolio offer diverse solution heartgard plus contain active ingredient ivermectin important need canine feline health include indus pyrantel soft beef chew give monthly tryleading parasiticide vaccine therapeutic address ivermectin effective prevent deadly heartworm dis major chronic disease heart failure kidney disease hyperten ease pyrantel effective treatment control round sion epilepsy osteoarthritis worm hookworm heartgard launch monthly heartworm preventative year frontline leader flea tick bestselle heartworm preventative world control dog cat trust brand animal health frontline continue bring innovation broadline offer pet owner allinone convenience provide category recent launch frontline triact confidence cat broad possible protection feature repellency insecticidal efficacy protect cat broadest spectrum internal disease carry fly insect decrease risk external parasite include adult flea flea eggs flea larvae transmission vectorborne pathogen tick heartworm hookworm roundworm tapeworm nexgard contain active ingredient afoxolaner new class heart treatment term inodilator oral medication treat flea tick dog vetmedin show significantly improve clinical efficacy palatable beefflavore soft chew sign extend life expectancy dog congestive heart formulation nexgard currently bestselle pet medica failure originating dilate cardiomyopathy valvular tion animal health industry insufficiency mitral andor tricuspid regurgitation recent study show preclinically appro nexgard spectra combine flea tick efficacy priate asymptomatic case dilate cardiomyopathy afoxolaner nexgard broadspectrum deworme doberman pinscher valvular insufficiency vetmedin sig ingredient milbemycin oxime beefflavored chew nificantly delay onset clinical sign congestive heart nexgard spectra effective treat flea failure tick protect dog deadly parasites heartworm lungworm gastrointestinal parasite datum file novel combination fipronil permethrin frontline triactfrontect reduce risk transmission babesia canis dermacentor reticulatus ehrlichia canis rhipicephalus sanguineus tick dog jongejan et al parasite vector datum file datum file product portfolio animal health indication brand name active ingredient antiparasitic caninefeline frontline fipronil frontline indicate treatment external parasite frontline combo fipronilsmethoprene prevention flea tick chew lice frontline plus fipronilpermethrin dog cat aid control frontline triact sarcoptic mange dog frontect frontline plus frontline combo indicate treatment prevention flea tick chew lice dog cat break flea life cycle prevent development immature stage aids control sarcoptic mange dog frontline triactfrontect indicate treatment prevention flea tick infestation repellent antifeeding activity necessary sandfly bite fly andor mosquito dog antiparasitic canine external nexgard afoxolaner nexgard deliver highly palatable parasite beefflavore chew kill adult flea indicate treatment prevention flea infestation treatment control tick infestation dog puppy month antiparasitic canine internal nexgard spectra afoxolaner nexgard spectra deliver highly external parasite milbemycin oxime palatable beefflavored chew kill adult flea indicate treatment prevention flea tick infestation pre vents heartworm disease treat con trols hookworm roundworm whipworm lungworm infestation dog puppy antiparasitic canine internal heartgard plus ivermectin use dog prevent canine heartworm parasite pyrantel disease eliminate tissue stage heartworm larvae month day infection treatment control roundworm hookworm antiparasitic feline internal broadline fipronil smethoprene protect cat broadest spectrum external parasite eprinomectin praziquantel internal external parasite include adult flea flea eggs flea larvae tick heartworm hookworm roundworm tapeworm congestive heart failure vetmedin pimobendan treatment canine congestive heart failure originating dilate cardiomyopathy valvular insufficiency mitral andor tricuspid regurgitation treatment dilate cardiomyopathy preclinical stage asymptomatic increase leave ventricular endsystolic enddiastolic diameter doberman pin scher treatment dog myxomatous mitral valve disease mmvd preclinical stage asymptomatic systolic mitral murmur evidence increase heart size delay onset clinical symptom heart failure boehringer ingelheim annual report companion animal pet continue metacam nonsteroidal antiinflammatory drug nsaid semintra firstever license angiotensin receptor available oral suspension tablet injectable blocker arb veterinary use provide proven conve solution dog oral suspension injectable nient safe compliance solution cat cat owner solution cat dog indication include allevia vets semintra available mgml mgml oral solu tion inflammation pain acute chronic mus tion semintra mgml launch culoskeletal disorder reduction pain follow reduction proteinuria associated chronic kidney dis ing surgery cat indication include alleviation ease ckd cat semintra mgml inflammation pain acute chronic musculoskeletal launch control ustreatment eu feline systemic disorder alleviation mild moderate hypertension vetlicense product feline postoperative pain variety formulation offer veteri hypertension narian owner flexibility use formulation prefer individual case manage level launch prozinc prove inflammation pain associate license indica choice feline patient owner convenient man tion agement feline diabete reliable longacte insulin treatment option difference previcox launch new nsaid selective life cat owner approval prozinc cox inhibitor dog address category canine patient opportunity expand main driver need efficacious pain relief ensure impact firstchoice solution successful man safety long term previcox indicate relief agement diabetes dog cat pain inflammation associate osteoarthritis relief postoperative pain inflammation associ pet vaccine product portfolio include purevax feline ate soft tissue orthopedic dental surgery vaccine formulate provide effective protection use adjuvant recombitek provide targeted protec tion dog recombinant technology product portfolio animal health indication brand name active ingredient pain inflammatory metacam meloxicam metacam reduce specific type disease postoperative pain inflammation musculoskeletal disorder dog cat pain inflammatory previcox firocoxib relief pain inflammation associ disease ate osteoarthritis specific type postoperative pain dog chronic kidney disease ckd semintra telmisartan management chronic kidney disease ckd cat feline systemic hypertension eu cat hypertension cat diabete prozinc protamine zinc treatment diabete mellitus cat dog achieve reduction hyper glycemia improvement associate clinical sign feline vaccine portfolio purevax feline herpes virus purevax fully adjuvantfree feline feline calicivirus vaccine range leverage innovative feline panleukopenia virus canarypox technology felv rabie chlamydophila felis offer sustained protection rabie recombinant vectore feline year leukemia virus recombinant vectore rabie virus canine vaccines portfolio recombitek recombinant vectore canine recombitek feature complete line distemper virus canine vaccine include canine parvovirus recombitek lyme vaccine canine adenovirus type contain ospa nonadjuvant formulation canine parainfluenza virus coronavirus rekombitek oral bordatella effective leptospira canicola safe protection easy leptospira grippotyphosa leptospira icterohaemorrhagiae leptospira pomona recombinant borrelia burgdorferi bordetella bronchiseptica othersboehringer ingelheim annual report ch boehringer sohn ag co kg ingelheim rhein comparison balance sheet financial datum million eur asset december intangible asset tangible asset financial asset fix asset inventory account receivable asset incl prepay expense defer taxis exceed plan asset liquid fund current asset total asset equity liability december shareholder capital group reserve incl balance sheet currency conversion difference group profit equity attributable parent company noncontrolle interest group equity difference capital consolidation provision incl defer taxis liability incl defer income total liability incl defer taxis defer income total equity liability summary select financial datum net sale operating income operating income net sale income taxis income taxis net sale return equity equity ratio cash flow operating activity financial fund personnel expense personnel expense net sale average number employee research development expense rd net sale investment tangible asset depreciation tangible asset p r n ch boehringer sohn ag co kg asset december binger strae intangible asset ingelheim rhein germany tangible assets telephone financial asset fax fix asset contact inventory corporate division communication public affair account receivable asset incl prepay expense matthias reinig defer taxis exceed plan asset email pressboehringeringelheimcom liquid fund internet wwwboehringeringelheimcom current asset issue total asset ch boehringer sohn ag co kg represent board manage director hubertus von baumbach chair equity liability december carinne brouillon dr michel pairet shareholders capital jean scheftsik de szolnok michael schmelmer group reserve incl balance sheet currency conversion difference concept design layout group profit mpm corporate communication solution mainz dsseldorf equity attributable parent company wwwmpmde noncontrolle interest photo group equity andreas reeg difference capital consolidation provision incl defer taxis print eberl print gmbh immenstadt liability incl defer income total liability incl defer taxis defer income copyright total equity liability ch boehringer sohn ag co kg right reserve annual report reproduce transmit form mean summary select financial datum electronic photocopy permission write net sale ch boehringer sohn ag co kg figure party annual report base datum available operating income time financial statement draw operating income net sale income taxis income taxis net sale return equity equity ratio cash flow operating activity financial fund personnel expense carbon neutral personnel expense net sale natureofficecom devebrj print production average number employee research development expense rd net sale co emission certificate support forest conservation forest modification region germany investment tangible asset depreciation tangible asset wwwboehringeringelheimcom annualreportboehringeringelheimcom